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Abstract
Although improvement in the detection and treatment of 
hypertension has occurred over the last two decades, the 
trends have stagnated over the last 5 years with a related 
increase in mortality from cardiac failure and an 
increased incidence of end-stage renal disease. Current 
researchers have made a strong argument that many health 
care providers have not been successfully managing 
hypertension at a level, as established by research, to 
prevent target organ disease over time. As health care 
providers, family nurse practitioners (FNPs) and adult 
nurse practitioners (ANPs) are managing hypertension in 
outpatient settings as primary care nurse practitioners 
(PCNPs). This descriptive study sought to answer two 
research questions: How effectively are PCNPs 
implementing the JNC VI guidelines for hypertension 
management in practice? And are PCNPs aware of the current 
national guidelines (JNC VI) for hypertension management? 
Ten critical factors/interventions were measured to 
evaluate compliance with the JNC VI guidelines and were 
analyzed with descriptive statistics of frequency. Data
111
analysis revealed that the PCNPs in the study were 
noncompliant with the use of the JNC VI guidelines in 
practice and encouraged recommendations in PCNP education 
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Cardiovascular disease has been cited by health care 
professionals as the main health problem facing the United 
States. Heart disease has been established as the number 
one cause of mortality in the United States with 724,859 
deaths in 1998 (National Center for Health Statistics,
1998). Over the last 30 years researchers have concluded 
that hypertension is a strong predictor of future 
cardiovascular disease and other target organ disease when 
uncontrolled (Belanger, Cupples, & D'Agostino, 1988; He & 
Whelton, 1999; Kennel, 1999) . This recognition of 
hypertension as a related cause of cardiovascular disease 
and other target organ diseases has led many developed 
nations to formulate national programs and guidelines for 
hypertension control.
The United States' version of a national hypertension 
control program was started in 1973 with the National 
Heart, Lung, and Blood Institute (NHLBI) establishing the 
National High Blood Pressure Education Program (NHLBI,
1997). The NHLBI formed a committee of professionals from
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various professional and governmental health care agencies 
to meet needs of inadequate detection and treatment of 
hypertension in the United States. The last committee 
appointed, the Sixth Joint National Committee for the 
Prediction, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC VI), met and created the most recent 
national guidelines for hypertension management in 1997. 
Over the last 27 years, health care providers implementing 
NHLBI guidelines have reduced the mortality rates for 
stroke and coronary heart disease significantly and 
increased the awareness and treatment of hypertension 
nationwide (NHLBI, 1997).
Although multiple and various methods of research, 
including controlled trials, were used in formulating 
these guidelines for hypertension management, many health 
care professionals are not complying with the guidelines 
in practice as revealed by current literature and 
statistics. This perplexing problem has a direct effect on 
the care provided to patients and motivated the current 
study to ascertain how primary care nurse practitioners 
(PCNPs) are managing their health problem. PCNPs treat and 
manage medical illnesses using standardized guidelines for 
practice in a medica/curing model. PCNPs also practice 
from a nursing/caring model that is influenced by nursing 
experience and education prior to specialized education in
3
the PCNP role. This researcher explored the role of PCNPs 
as a separate population from physicians to determine how 
they approached hypertension management, especially in 
regard to compliance with national hypertension 
guidelines.
Establishment of the Problem
Hypertension management in the United States has been 
a concern of almost all health care providers because of 
the strong causal and predictive relationship to 
cardiovascular disease, cerebrovascular disease, end-stage 
renal disease, peripheral vascular disease, and other 
target organ disease (Belanger et al., 1988; He & Whelton, 
1999; Kennel, 1999; Stamler, Stamler, & Neaton, 1993). Due 
to this recognition of hypertension as a causative factor 
for significant amount of mortality and morbidity 
worldwide, most developed countries have endorsed national 
hypertension control programs. In the United States, the 
NHLBI has appointed a joint national committee every 5 
years since 1973 to study and update national guidelines 
for health care professionals to use for hypertension 
management. The JNC VI revealed some alarming trends over 
the last 5 years that suggest the need for improvement in 
hypertension management strategies by health care 
providers (NHLBI, 1997). The areas of greatest concern
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were an increase in the incidence of mortality from 
cardiac failure, an upsurge in the incidence of end-stage 
renal disease (ESRD), and a slight statistical rise in the 
incidence of age-adjusted stroke rates (NHLBI, 1997). The 
JNC VI determined that hypertension is "the second most 
common antecedent" in ESRD and a "common antecedent" in 
heart failure (NHLBI, 1997, p. 5).
Cardiovascular disease and stroke are very costly in 
health care dollars spent in the care for these diseases. 
The JNC VI reported that cardiovascular disease costs 
"impose an enormous financial burden on Americans [with] 
more than $259 billion in direct and indirect cost 
[yearly]" (NHLBI, 1997, p. 7). Current researchers believe 
that part of this problem is related to failure to follow 
established hypertension management guidelines and 
personal clinical practice beliefs of health care 
providers in current practice that are not established 
through research (Dustan, 1998; Perry et al., 1998 ;
Swales, 1999). Although the JNC VI has recommended that 
health care providers control their patients' blood 
pressure at a level of < 140/90 mmHg to prevent target 
organ disease and optimally < 120/80 mmHg, current 
researchers argue that this is not being done effectively 
(Berlowitz et al., 1998; Dustan, 1998; Perry et al., 1998; 
Swales, 1999).
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Health care providers are overlooking systolic 
hypertension, especially in the elderly, due to beliefs 
that it is too variable to be a predictor of 
cardiovascular disease (Berlowitz et al., 1998; Dustan, 
1998 ; Swales, 1999). One study. Current Clinical Practice 
in Hypertension: The EISBERG project (Swales, 1999), 
exemplified the current inadequate hypertension control. 
The EISBERG project made a strong argument that systolic 
hypertension is not being controlled effectively in the 
United States and in six other developed countries. This 
project used a quantitative analysis of data received from 
seven countries, 1,486 general practitioners, and 17,359 
patients to discover some unsettling findings. Only 49% of 
patients in the study were controlled at a blood pressure 
< 160/90 mmHg and only 30% to the level of < 140/90 mmHg 
as established by the JNC VI and other countries' 
hypertension guidelines. This example of ineffective 
systolic hypertension was consistent with the statement by 
the JNC VI, "nearly three-fourths of adult Americans with 
hypertension are not controlling their blood pressure to 
below 140/90 mmHg" (NHLBI, 1997, p. 8). Similarly, 
statistics reported by the Third National Health and 
Nutritional Survey show that "69% of hypertensive subjects 
were aware of [their] elevated blood pressure, 53% were
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receiving treatment, and 24% were controlled" (Swales,
1999, p. 232).
The EISBERG project results also imply that systolic 
blood pressures have not been as rigidly controlled as 
diastolic blood pressures. The authors reported that more 
than 50% of the sample patients had a diastolic blood 
pressure controlled to a level endorsed by their country's 
national guidelines, but less than 40% of the patients had 
a systolic blood pressure controlled at this level. Swales 
(1999) concluded that part of this mismanagement of 
systolic blood pressure was due to some physicians having 
"a skeptical [belief] about the significance of systolic 
blood pressure . . .  it was too variable to be a reliable 
predictor of cardiovascular risk [and] diastolic blood 
pressure is more readily controlled" (p. 234). This 
opinion was generated following the analysis of the 
qualitative data on hypertension management beliefs 
received during the study which included opinions of 30 
general practitioners.
Other results in the EISBERG project implied that a 
patient's age affected hypertension control. For example, 
the general practitioners who were interviewed treated 
patients older than 65 years less aggressively, as the 
majority did not institute pharmacological treatment until 
blood pressure was 170/100 mmHg (Swales, 1999). The
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EISBERG project, along with an advisory statement from the 
NHLBI (Izzo, Levy, & Black, 2000), highlighted a belief by 
some physicians that an elderly person's age plus 100 mmHg 
was an appropriate blood pressure. These beliefs and 
treatment practices are not congruent with the JNC VI 
guidelines or recent research findings which stated that 
systolic hypertension is a strong predictor of 
cardiovascular disease and should not be overlooked as a 
natural part of aging as blood vessels lose their 
elasticity (Belanger et al., 1988; He & Whelton, 1999; 
Kennel, 1999; Staessen et al., 2000; Stamler et al.,
1993). Izzo and his colleagues reviewed results from the 
Lloyd-Jones (1999) study which used data from the 
Framington Heart Study cohort to measure systolic 
hypertension's ability to predict need for pharmacologic 
treatment. Izzo et al. stated that "systolic blood 
pressure alone correctly classified blood pressure stage 
in 91 percent of individuals who were potential candidates 
for antihypertensive therapy compared to 22 percent who 
were correctly classified using diastolic blood pressure 
values" (Izzo et al., 2000, p. 2).
Uncontrolled systolic hypertension is a strong 
predictor of a stroke and is a prevalent cause of 
mortality nationwide (He & Whelton, 1999; Kennel, 1999; 
Staessen et al., 2000; Stamler et al., 1993). The National
8
Center of Health Statistics (NCHS) report that stroke is 
the third cause of death in the United States. However, 
Mississippi, the main setting for this study, has an 18% 
higher stroke rate than the national average as reported 
by the American Heart Association (Penman & Johnson,
2000). Another alarming statistic for the state of 
Mississippi concerning mortality related to strokes was 
that one fourth of the stroke-related deaths were in 
patients less than 65 years of age (Penman & Johnson,
2000). The detection and treatment of hypertension have 
been a problem in Mississippi. Approximately one third of 
the state's population has hypertension, and one third of 
those citizens with hypertension have not been diagnosed 
(Penman & Johnson, 2000). Of those diagnosed, "half are 
not on treatment, for one reason or another" (Penman & 
Johnson, 2000, p. 9). The problems with detection of 
hypertension may be attributed to a lack of access to a 
provider in many outlying rural areas in Mississippi.
Family nurse practitioners (FNPs) and adult nurse 
practitioners (ANPs) are primary care providers that work 
in rural areas to meet the health needs of these 
underserved populations. These PCNPs are educated to 
detect and treat hypertension as part of their advanced 
practice role. PCNPs use scientifically supported medical 
research to guide their practice. PCNPs also are educated
to use guidelines for practice with various disease 
processes. PCNPs in this respect follow a medical/curing 
model when approaching patient care.
On the other hand, PCNPs are registered nurses who 
have received education as advanced practice nurses to 
approach patients from a nursing/caring model. This is 
important as the nursing/caring model stresses the 
importance of health teaching and promotion with close 
contact with the patient. Although recent research has 
sought to determine the degree of satisfaction related to 
performance of care between physicians and nurse 
practitioners (NPs) by patients, no research was found 
that studied PCNPs as a separate population in regard to 
their compliance with medical guidelines in practice. This 
current researcher sought to add to the scientific 
foundation of nursing by evaluating PCNPs' ability to use 
the JNC VI guidelines in practice. Implementation of this 
descriptive research was important to evaluate the care 
for patients with hypertension across the adult life span. 
Analysis of the research data can be used to formulate 




Although improvements concerning nurse practitioner
professional practice issues have been addressed through
state and national legislation, some physicians are still
fighting NPs at every turn regarding their professional
scope of practice. A recent legislative update concerning
NP practice issues stated, "The AMA has an intensive
online advocacy campaign to help medical societies defeat
state and national legislation that improves practice
authority of APN and other providers . . .  as part of the
AMA's plan to sustain physician control over other
providers" (Pearson, 2001, p. 14). The AMA, according to
the author of the update,
. . . submitted a "Citizens Petition" to the
HCFA in July 2000 [which] . . . insists that NPs
and CNSs should be forced to work in 
collaboration with physicians, [that] HCFA has 
failed to uphold the intent of Congress and its 
duty to taxpayers and medical beneficiaries by 
encouraging APNs to practice beyond legally 
authorized safeguards. (Pearson, 2001, p. 14)
Although recent studies have supported the NP's
ability to competently care for patients while being
economically conscientious, NPs still face many
professional practice issues, such as (a) direct
reimbursement, (b) prescriptive authority restrictions,
(c) hospital privilege restrictions, and (d) limited scope
of practice concerning medical procedures (Pearson, 2001).
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One main issue affecting many NPs is legislation 
controlling prescriptive authority. Currently, the 
majority of states (N = 38) in the United States require 
NPs to have physician's involvement, with prescriptions 
written with their name on the prescription pad or 
delegation by physicians concerning medications that can 
be prescribed in practice (Pearson, 2001). Although many 
studies have been performed concerning NPs' ability to 
care for patients in various medical settings with diverse 
medical populations, some controversy remains regarding 
NPs receiving enough pharmacological education to be 
competent in prescriptive practice. A review of the 
literature concerning NPs' prescriptive competence yielded 
no results on different pharmacologic classes of 
medication. Further outcome research concerning competent 
prescriptive practice of various pharmacologic classes of 
medication is needed to push future legislation to respect 
the NP's ability to competently prescribe all classes of 
medication without physician supervision or delegation.
This research aims to add scientifically relevant data to 
help fill this gap in outcome-based, nurse practitioner, 
prescriptive practices by focusing on how NPs follow 
national guidelines in treating hypertension (HTN) with 
antihypertensive medications along with other 
nonpharmacologic measures. Results from studies on NP
12
prescription practice along with future outcome oriented 
research concerning NP treatment methods should allay 
fears by the health care consumer, give confidence to 
legislators involved in NP professional practice issues, 
and subdue doubt and argumentation of the aforementioned 
health care providers.
Theoretical Framework
Imogene King's Theory of Goal Attainment was the 
theoretical framework used to guide the study. In King's 
Theory of Goal Attainment, a dyad, or group of two people, 
come together to form an interpersonal system. This 
interpersonal system relies on communication to provide 
interaction between the two people in the dyad (King,
1981). The PCNP and the patient with hypertension 
exemplify the dyad in this study. King explained in her 
theory that interaction allows the nurse to develop a 
model of transaction/interaction that shares theoretical 
knowledge used by nurses to help individuals and groups 
achieve their goals (King, 1981). Mutual goals toward 
health are formed and agreed upon by the nurse and patient 
and include the following steps: "(a) nurses' assessment 
of a client's concerns, problems, and disturbances in 
health; (b) [the] nurse's and client's perception of the 
interference; [and] (c) their sharing of information
13
whereby each functions to help the client attain the goals 
identified" (King, 1995, p. 28).
Transaction is explained as a process in which both 
the nurse and the client perform actions together to meet 
a goal they have agreed upon. This process depends on the 
nurse, or in the current study, the PCNP, to "communicate 
appropriate information to clients" (Tomey & Alligood,
1998, p. 306) to allow mutual goal setting and attainment 
to occur. The PCNP must be knowledgeable about current 
modalities of treatment and management of disease process 
to be effective in this process. Hypertension management 
can be controlled by both lifestyle modification and 
pharmacological treatment. The PCNP should be aware of the 
most current, effective treatment interventions in regard 
to hypertension management to efficiently formulate 
competent treatment regimens for hypertensive patients.
There also is a need for mutual goal setting between 
the PCNP and the patient in this process to ensure patient 
compliance with a treatment regimen. Antihypertensive 
medications have various side effects that are worrisome 
to patients and cause these patients to alter the 
prescribed antihypertension medication regimen. Some 
hypertensive patients are not aware of arteriosclerosis 
and hyperlipidemia, along with other lifestyle factors as 
scientific evidence of hypertension. PCNPs should
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constantly interact with these patients and determine 
their perception of treatment interventions in an effort 
to formulate goals toward hypertension management and 
ensure compliance. King states in her theory, "if 
perceptual accuracy is present in nurse-client 
interactions, transactions will occur, [and] if nurse and 
client make transactions, goals will be obtained" (Tomey & 
Alligood, 1998, p. 306).
Assumptions
The following assumptions were made in formulating 
the design and are regarded as principles that are 
believed to be true and relevant to the current research:
1. PCNPs value established research on medical and 
nursing treatments as the foundation for competent 
practice.
2. The JNC VI guidelines for hypertension management 
are valid for the management of hypertension and are 
adequately backed by scientific research.
3. PCNPs have the proper education and clinical 
preparation to effectively predict, detect, evaluate, and 
treat hypertension.
4. PCNPs can be effective in the management of 
disease process in patients through use of mutual goal
15
setting by sharing specialized knowledge contained in 
guidelines for medical practice.
Statement of the Problem
Hypertension detection and treatment have improved 
over the last two decades, but the trends have stagnated 
over the last 5 years with an increase in the incidence of 
mortality from cardiac failure and an increased incidence 
of end-stage renal disease (NHLBI, 1997). This dilemma is 
largely due to mismanagement of systolic blood pressure at 
parameters > 140 mmHg despite valid research that systolic 
blood pressure is a strong predictor of future 
cardiovascular and renal disease. Many health care 
providers still hold beliefs that systolic blood pressure 
is too variable to be an adequate predictor of future 
cardiovascular disease (CVD). These health beliefs are not 
supported by scientific research and are inconsistent with 
national guidelines that support a blood pressure 
measurement of < 140/90 mmHg, especially in elder clients 
to prevent further target organ disease (NHLBI, 1997).
PCNPs may not be managing high blood pressure by 
using national guidelines despite adequate research which 
asserts that high blood pressure maintained at a level > 
140/90 mmHg puts patients at risk for target organ 
disease. This researcher explored how compliant PCNPs were
16
in using the scientifically backed JNC VI recommendations 
for hypertension management.
Research Questions
For this study, the following research questions were 
formulated :
1. How effectively are PCNPs implementing the JNC VI 
guidelines for hypertension management in practice?
2. Are PCNPs aware of the current national guidelines 
(JNC VI) for hypertension management?
Definition of Terms
The following concepts, essential to the study, were 
defined to help the reader better comprehend their 
meaning. The theoretical definition is the definition of 
the concept as it relates to the literature reviewed for 
the study. The conceptual definition is the operational 
definition or how the concept is used in the study.
Primary care nurse practitioner (PCNP): Theoretical: 
a licensed, certified, advanced practice nurse, who acts 
as a primary care provider and provides medical care to 
patients of various ages within a family. Conceptual: 
family nurse practitioner or adult nurse practitioner, 
certified and licensed in the state of Mississippi, 
performing the role of a primary care provider, who has at
17
least 1 year of experience and practices in Mississippi, 
Alabama, Tennessee, or Louisiana.
Hypertension management: Theoretical: maintenance of 
a blood pressure measurement within the prescribed JNC VI 
parameter to prevent the onset, or progression, of target 
organ disease in a patient medically diagnosed with or in 
treatment for hypertension. Conceptual: the maintenance of 
a blood pressure measurement < 140/90 mmHg without organ 
disease and a blood pressure measurement of < 130/80 mmHg 
with target organ disease in a patient, 35 to 55 years of 
age, to prevent onset or progression of target organ 
disease.
JNC VI guidelines. Theoretical: " . . .  national 
guidelines formulated by the National High Blood Pressure 
Education Program of the National Heart, Lung, and Blood 
Institute to predict, detect, evaluate, and treat 
hypertension" (NHLBI, 1997, p. 5). Conceptual: national 
guidelines formulated by the National High Blood Pressure 
Education Program of the National Heart, Lung, and Blood 
Institute to predict, detect, evaluate, and treat 
hypertension. PCNPs' compliance with, and awareness of, 
the national hypertension management guidelines (JNC VI) 
were measured using 10 critical factors identified on 
Cagle's JNC VI Guidelines Compliance Survey.
Chapter II 
Review of the Literature
A review of the literature was performed to validate 
and establish a need for this study on PCNPs and 
hypertension guidelines compliance. Very limited research 
was found to support the concepts, and only one set of 
researchers discussed nurse practitioners (NPs) in 
hypertension management using national hypertension 
guidelines. The limited amount of research found was in 
itself an indication of the need for research, and the 
literature found did make a sound argument for this study 
and is made evident by findings reviewed in the studies 
that follow.
Goldberg et al. (1998) directed their research to 
evaluate how effective continuous quality improvement 
(CQI) teams and academic detailing (AD) were in producing 
change in clinical practice concerning hypertension (HTN) 
and depression. The research problem as identified by the 
authors was, although clinical guidelines for practice 
have been developed and disseminated over the last two 
decades, compliance by health care providers has been very
18
19
minimal (Goldberg et al., 1998). AD and CQI have been 
successful methods for altering practice in medication 
prescription practice and industrial management, but have 
not been studied in regard to chronic disease and 
treatment (Goldberg et al., 1998). Thus, the researchers 
listed three research questions:
1. How well were the AD techniques and CQI team 
interventions implemented within clinics?
2. How effective were both interventions in 
increasing compliance with guideline recommendations 
across clinics?
3. If variation in implementation was observed, were 
instructive associations between implementation success 
and outcome improvement demonstrated?
Academic detailing was defined as "one-on-one 
education and feedback sessions" (Goldberg et al., 1998, 
p. 130) provided by experts concerning guidelines for 
clinical management of HTN and depression, and CQI teams 
as "a model in which entire organizations commit to 
reducing unwanted practice variation at all levels" 
(Goldberg et al., 1998, p. 131). Blood pressure control 
was defined as a blood pressure measurement < 160/90 mmHg, 
and a diastolic blood pressure measurement < 80 mmHg was 
described as over-controlled (Goldberg et al., 1998).
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The study design used was a descriptive, pretest- 
posttest experimental design which gathered baseline data 
for 12 months, followed by 6 months of intervention with 
AD, CQI, or both, and then re-gathered data for 12 months 
post-interventions. Four clinical sites in the Seattle, 
Washington, area provided the settings. Two of the clinics 
were HMO affiliated, one was a university-based hospital 
and the last site was a veterans clinic.
A blocked and randomized sampling design was utilized 
and consisted of 15 small groups of health care 
practitioners including 95 health care providers and 4,955 
patients in total. The patients were by majority Caucasian 
(> 84%) and male (> 51.4%). The majority of physicians 
{> 7 4%) represented were internal medicine practitioners 
as a speciality. The patients used in the HTN portion of 
the study were "known hypertensives" and described as 
"patient with a mean blood pressure value > 160/90" 
(Goldberg et al., 1998, p. 133). Differences between 
samples were compared through the use of analysis of 
variance and contingency table analysis, as data were 
received from seIf-administered questionnaires and surveys 
(Goldberg et al., 1998). There was a control group for the 
study which received usual care (UC) during the study to 
compare the results.
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The AD intervention was performed by two physicians
at each site giving 15-minute lectures on information from
guidelines for hypertension, followed by two follow-up 
sessions conducted by pharmacists concerning prescription 
patterns.
The CQI teams were implemented by CQI facilitators 
for the first couple of months of the study and then 
supervised by physician team leaders. The CQI facilitator 
trained physician team leaders in "team based approaches 
. . . to improve quality" and informed team on change
process by facilitating the "Shewart cycle of activities 
. , . [to] plan, do, study, act" (Goldberg et al., 1998, p.
132). Each team collected its own data at its own pace and
was free to choose interventions to change processes as 
problems presented themselves during the data collection. 
The only limitation was that interventions had to be 
geared toward the five recommendations formulated for HTN 
and depression.
The recommendations related to hypertension were (a) 
the prescribing of beta-blockers and potassium-sparing 
diuretics specifically promoted, (b) the prescribing of 
calcium channel blockers and ACE inhibitors were "to be 
reserved for special indications or when first-line drugs 
have proven ineffective," and (c) blood pressure control 
to be performed without placing patients at risk for
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"over-control" (Goldberg et al., 1998, p. 132). There were 
three to five groups at each site participating in the 
study receiving either AD, CQI, both, or UC. The 
instruments for data collection were varied from 
information systems in pharmacy to collect prescription 
patterns to written charts in the hypertension portion of 
the study.
Data were analyzed using mean percentages for all 
clinics and highest percentage change as "best case 
clinic" to reflect changes following interventions and 
compared to usual care (UC). Differences between samples 
were compared through the use of analysis of variance and 
contingency table analysis, as data was received from 
self-administered questionnaires and surveys. Pairwise t 
tests were used to distinguish changes of one intervention 
in comparison with the others and usual care. The samples 
were designed to give a good degree of power (80%) in 
revealing a 10% change as HTN control (Goldberg et al.,
1998).
There were only two significant findings (p < .05).
In the county, Harborview Medical Center, AD + CQI were 
statistically significant (p = .01) in producing an 
increased change in the prescription of diuretics as 
compared to UC. The other significant finding (p = .00) 
was in regard to AD + CQI teams versus AD in increasing
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the percentage of diuretic prescription in the same 
setting. There was less than a 3.8% mean increase in 
prescription patterns of diuretics, potassium-sparing 
regimens, and beta-blockers in groups where AD, or AD and 
CQI, interventions were implemented. Ironically there was 
a higher percentage change in usual care patterns, with 
the highest percentage improvement (+6.3% mean) for all 
clinics in potassium-sparing regimens. There was only 
slight improvement in beta-blocker prescribing (+3.7% 
mean) in AD + CQI groups versus usual care (+3.1% mean) 
(Goldberg et al., 1998). The decrease percentage in the 
prescription of calcium channel blockers (-1.3% mean) and 
ACE inhibitors (+1.3% mean) was also very poor as compared 
to usual care changes for calcium channel blocks (-4.6% 
mean) and ACE inhibitors (+2.1% mean). The analysis of 
blood pressure control improvement means were also dismal, 
with only an 8.2% increase in control for AD groups and a 
3.9% increase in AD + CQI groups compared to a 9.6% 
improvement in the usual care group. There was an increase 
in over control of blood pressure, as defined by the 
study, in all groups with a 3.1% increase in AD groups, a 
7.8% increase in the AD + CQI groups, and a 10.6% increase 
in the UC group (Goldberg et al., 1998).
The researchers concluded, "neither the AD nor the 
CQI team interventions . . . were associated with
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improvement in prescribing patterns or control rates in 
regard to guideline recommendations across clinics" 
(Goldberg et al., 1998, p. 132). This conclusion 
illustrates that although reliable scientific research has 
been established to improve treatment clinical 
practitioners have failed to alter their management. 
Although AD and the CQI techniques were performed 
adequately in the setting there was a high degree of 
freedom given to each setting concerning choices for 
"process change and in identifying process deficiencies" 
(Goldberg et al., 1998, p. 132). Due to this freedom, it 
is possible that the AD and CQI methods may have been 
performed differently in these settings and had an effect 
on findings, but the homogeneity of results being 
nonsignificant suggests that this was not the case.
The authors concluded that implementation of the AD 
or CQI modalities was unlikely to produce any change in 
compliance with established national guidelines for 
practice and that CQI teams "may benefit from focusing 
more on implementing process changes with . . .
established effectiveness" (Goldberg et al., 1998, p.
141). NPs, although a minority in number, were included in 
the study with no stratification given as far as their 
number in the composition of the veterans clinic portion 
of the sample.
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NPs depend on medical models for practice and the 
physician as a professional resource. NPs need to be able 
to distinguish practice that is scientifically sound as 
compared to traditional or personal preferences in 
practice. Research is needed to evaluate NPs' management 
of HTN in their clients and their knowledge of national 
guidelines.
Another study, Siegel and Lopez (1997), investigated 
physician prescription patterns of antihypertension 
medications 3 years after the initiation of the Fifth 
Joint National Committee on Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC V ) . The research 
question was as follows: Do the JNC V recommendations 
affect prescribing? The JNC V recommendations that 
received significant focus were hydrochlorothiazide (HCTZ) 
and beta-blockers as first-line antihypertensives in the 
treatment of hypertension due to their results in reducing 
"cardiovascular mortality and morbidity . . .  in long-term 
controlled clinical trials" (Siegel & Lopez, 1997, p.
1745). The researchers recognized that use of this 
treatment was based on the absence of contraindications or 
unacceptable circumstances for prescription (Siegel & 
Lopez, 1997). The variables under examination in this 
study were prescriptions written for hypertensive patients 
over a 3-year span. There were 200 medications that were
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determined to be the most frequently prescribed and were 
calculated by information collected by Scott-Levin through 
surveys to retail pharmaceutical companies (Siegel &
Lopez, 1997). The conceptual framework focused on the JNC 
V guidelines and the impression that some physicians are 
in disagreement with these guidelines.
Siegel and Lopez (1997) used a prospective, 
descriptive design that selected retail pharmacies as the 
population for the study. Retail pharmacies were defined 
as any of the following: chain pharmacies (27%), 
independent pharmacies (18%), pharmacy in mass merchandise 
stores (8%), and other (4%) (Siegel & Lopez, 1997). The 
retail market defined above was stated to "disperse 
approximately 68% of all pharmaceuticals and diagnostics 
in the United States" (Siegel & Lopez, 1997, p. 1746). The 
35,000 retail pharmacies included in the study were drawn 
randomly from all 50 states in the United States. The 
population of retail pharmacies from which the sample was 
chosen was divided into 1,300 zones before being randomly 
selected. After being chosen, the retail pharmacies in 
each zone were evaluated for homogeneity in regard to 
prescription patterns using analysis of variance. Any 
zones with a large degree of variance in prescribing 
patterns were redefined to ensure homogeneity (Siegel & 
Lopez, 1997).
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The frequency of a medication being prescribed was 
determined using data collection from the retail 
pharmacies during the 3-year study. National figures for 
prescriptions given from the pharmacies in the study were 
calculated by multiplying the number of prescriptions in 
one zone by a "zone area projection factor." This factor 
was determined by "dividing the total number of 
prescriptions dispensed for all [medications] by all 
retail pharmacies in the zone by the number of [one 
specific medication prescribed in that zone by all retail 
pharmacies]" (Siegel & Lopez, 1997, p. 1746). Thus, the 
data collected from all pharmacies in the study, which 
represented an estimate of 70% of all prescriptions in the 
United States for retail pharmacies, were projected to 
estimate all prescriptions prescribed by retail pharmacies 
in the United States.
During the analysis of data, the prescriptions were 
gathered into antihypertensive classes for the years 1992 
and 1995, and the estimated mean for frequency of 
prescription was calculated from the total projected 
number of medications prescribed nationwide in retail 
pharmacies. The estimated total wholesale cost of each 
drug class prescribed was also calculated. The cost 
analysis was performed using "the average wholesale price
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as published in the 1995 Drug Topic Handbook" (Siegel &
Lopez, 1997, p. 1746).
The researchers reported an increase in the 
prescribing of calcium antagonist and ACE inhibitors and a 
reduction of diuretics and beta-blockers from 1992 to 
1995. In the year 1992, 33% of antihypertensives 
prescribed were calcium antagonists and increased by 5% in
1995 to 38%. In the year 1992, 25% of the prescriptions
were ACE inhibitors and increased 8% in 1995 to 33%. Beta- 
blocker prescriptions fell in number from 18% of all 
antihypertensive prescribed in 1992 to 11% in 1995, and 
diuretic prescriptions were cut in half with a drop from 
16% in 1992 to only 8% in 1995 (Siegel & Lopez, 1997). 
There was also a tremendous cost associated with the 
prescription of calcium antagonist and ACE inhibitors when 
compared to the cost of diuretics and beta-blockers. The 
following cost analysis of calcium antagonist and ACE 
inhibitor and diuretics and beta-blockers was contained in 
the study:
The estimated US wholesale cost to retail 
pharmacies for calcium antagonists was $2.67 
billion in 1992 and $2.86 billion in 1995. Costs 
for ACE inhibitors increased from approximately 
$1.37 billion to $1.67 billion. Costs for the 
diuretics decreased from $353 million to $168 
million, while costs for the beta-blockers 
decreased from $763 million to $433 million 
during the same time period. (Siegel & Lopez,
1997, p. 1747)
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If diuretics had been 38% of the prescribed 
antihypertensives for 1995, based upon previous figures, 
their cost would have been less than $1 billion as 
compared to the cost of the calcium antagonist ($2.86 
billion) and ACE inhibitors ($1.67 billion). Similarly 
beta-blockers also are cheaper in cost. Beta-blockers had 
an 11% prescription rate as compared to other 
antihypertensives and an estimated cost of $433 million in 
1995. If the beta-blocker prescription rate had been 33%, 
or three times what it was in 1995, then the associated 
cost, based upon figures above, would have been 
approximately $1.2 billion. Siegel and Lopez supported 
this opinion by asserting, "In 1995, based upon the 
estimates herein the cost of each 1% of the national use 
of the calcium antagonist was $75 million, while the cost 
of each 1% of diuretic use was $21 million" (Siegel & 
Lopez, 1997, p. 1748).
The results of this study provided evidence that 
national guidelines concerning hypertension management do 
not affect prescription practices by health care providers 
despite long-term controlled trials that support its 
prescription practice recommendations. There were no 
recommendations concerning the noncompliance implied by 
the analysis of the data, but it is not difficult to 
understand that the implications of noncompliance are
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costly. Siegel and Lopez do give some possible causes for
the noncompliance to the JNC V guidelines including
Reduced results of diuretics and beta-blockers 
in reducing coronary artery disease, 
individualization of treatment based upon other 
conditions, lack of dissemination of JNC V 
recommendations, the attractiveness of using new 
therapies, and the sale tactics of 
pharmaceutical companies for the newer 
antihypertensives, (p. 1748)
Further study with health care personnel in primary care,
such as family nurse practitioners (FNP), is needed to
evaluate if noncompliance with national guidelines
concerning prescription practice is prevalent in specific
settings with specific health care practitioners.
Perry et al. (1998) provided supportive data that
validated the competency of the JNC VI guidelines in
regard to antihypertensive medication prescribing. This
study also looked at hypertensive patients whose
hypertension was managed by "nurses and physician
assistants intensively trained in hypertension management"
(Perry et al., 1998, p. 771) as primary care providers.
Thee primary care providers used national hypertension
treatment guidelines written by the National High Blood
Pressure Education Program (NHBPEP) and Joint National
Commission of Detection, Evaluation, and Treatment of High
Blood Pressure (JNC) in treatment (Perry et al., 1998).
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The authors were concerned with examining 12 
different antihypertensive medication regimens chosen for 
treatment at Veterans Administration (VA) clinics and 
their efficacy in controlling hypertension. The variables 
examined were anti-hypertensive medication regimens as the 
independent variable and hypertension measurement as the 
dependent variable. There were two research questions to 
be answered by this study:
1. Which antihypertensive drugs were selected by the 
involved health care providers?
2. How effective [the antihypertensive drugs] were in 
achieving normotension?
The study was part of a Hypertension Screening and 
Treatment Program (HSTP) established by the Department of 
Veterans Affairs to provide hypertension treatment to 
veterans and was performed over 46 months from May 1989 to 
February 1993. The authors described normotension as a 
diastolic blood pressure measurement goal of 99 mmHg. 
Hypertension measurements were determined by an average of 
three readings "in minimally stressful conditions, with 
standardized mercury sphygmomanometers" (Perry et al.,
1998, p. 722). The 12 antihypertension medication regimens 
were defined as
(a) ND, no antihypertensive therapy, (b) D,
diuretic, (c) B, beta-blocker, (d) A, ACE
inhibitors, (e) C, calcium antagonist, (f) OD,
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other single antihypertensive drug, (g) D + B, 
diuretic plus beta-blocker, (h) D + S, diuretic 
+ non-beta blocker symptholytic agent, (i) D +
A, diuretic + ACE inhibitor, (j) D + C, diuretic 
+ calcium antagonist, (k) D + OD, diuretic + 
single antihypertensive agent not listed above, 
and (1) other. (Perry et al., 1998, p. 772)
A descriptive correlational design was used in this
study and was interested in looking at the frequency of 12
different antihypertensive drug regimens prescribed by the
health care providers in the study and the medication
regimens efficacy in controlling hypertension by
correlating each regimen's outcome to the outcome of other
regimens in the study. The researchers imposed no control
over the independent variable of antihypertensive
medication regimens in this study. The population for the
study was hypertensive veterans using VA clinics for
treatment of their hypertension. A convenience sample of
6,100 veterans who visited one of six HSTP clinics were
chosen for the study. The cohort studied was mainly male
(> 98%), older than 60 years of age (> 55%) and equal in
regard to Caucasian race (50%) and minority race (50%).
The patients were observed and followed for hypertension
data for an average of 6.4 + 5.7 years and had a mean
blood pressure of 148/92 mmHg upon entering the HSTP. The
settings for the study were six HSTP clinics in a wide
variety of geographical areas including the following :
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Indianapolis, IN; Jackson, MS; Memphis, TN; St. Louis, MO; 
Iowa City, 10; and San Juan, Puerto Rico.
Data were collected from the sample (N = 6,100) using 
two forms. The first form gathered demographic and pre- 
HSTP data including age, race, sex, height, past and 
family histories, years of education, and marital status 
(Perry et al., 1998). The second form was used in two 
areas of data collection. First, it was used at each 
clinic visit to gather a self-reported compliance with 
antihypertensive drug regimen, an average of three blood 
pressure readings, symptoms of treatment and severity, 
medical history changes during time of study, other 
medications, and weight. Second, it was used yearly to 
evaluate alcohol intake, tobacco use, any abnormal 
physical signs observed during treatment, and incidence of 
target organ disease, and to document lab data (Perry et 
al., 1998). Data were collected and analyzed over a 46- 
month period from 41,498 clinic visits.
The most frequently used antihypertensives were 
diuretics (54%) with the majority of these diuretics being 
hydrochlorothiazide (55%). The next most frequently used 
antihypertensive drug regimens were calcium antagonists 
(33%). Analysis of systolic blood pressure and diastolic 
blood pressure in relationship to the medication regimens 
was performed. Diuretics and beta-blockers used in
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combination provide the lowest average systolic blood 
pressure (140.1 mmHg) and calcium antagonist the highest 
(149.0 mmHg) (Perry et al., 1998). Diuretics also provided 
the lowest average diastolic blood pressure results (81.9 
mmHg) in the study and calcium antagonist the highest 
average (86.5 mmHg). Out of the six clinics, the three 
that used diuretics more than newer anti-hypertensive 
agents of ACE inhibitors and calcium antagonists had an 
average 6.2 mmHg lower systolic blood pressure in patients 
(141.8/147.0) and a 5.7 mmHg lower average diastolic blood 
pressure (82.0/87.7) (Perry et al., 1998). The researchers 
used a two-factor ANOVA to analyze differences between all 
regimens. The difference of results in regimens analyzed 
in the seven most common regimens were considered 
significant (p < .0001) and included the following drug 
classes in the regimens either alone or in combination :
(a) diuretic, (b) beta-blocker, (c) ACE inhibitor, and (d) 
calcium antagonists. Of all the regimens used, patients 
who were on diuretics needed the least amount of change in 
medication therapy (4 6% not needing change) as compared to 
patients on ACE inhibitors or calcium antagonist (18% not 
needing change).
The authors concluded that "for the elderly cohort 
and the clinical condition described here, the diuretic 
was a more potent antihypertensive agent than was the
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calcium antagonist" (Perry et al., 1998, p. 111). Also, 
diuretics and beta-blockers were associated with both 
lower average blood pressures (both systolic and 
diastolic) and lower percentage of lower uncontrollable 
blood pressures (14.9%/28%) than calcium antagonists. The 
health care providers were noncompliant with JNC V 
guidelines to control systolic blood pressure < 140 mmHg, 
and 5% had a treated systolic blood pressure > 180 mmHg. 
This noncompliance may be partially due to no set goal for 
systolic blood pressure in the study, but the health care 
professionals were aware of national guidelines for 
treatment of systolic blood pressure as stated by the 
researcher in regard to the health care professionals 
using National High Blood Pressure Education Program and 
JNC guidelines in treatment. This study provides data that 
nurses and physician assistants, when competently using 
national hypertension treatment guidelines, can 
effectively control hypertension to goal levels agreed 
upon normotensive. The study, however, does show evidence 
that, despite the use of national treatment guidelines for 
hypertension, these health care professionals were not 
compliant in controlling systolic hypertension to a level 
established by the JNC guidelines. Further research must 
be done to isolate NPs as a population in treating 
hypertension to see if they are aware of hypertension
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guidelines, implement these guidelines in practice, and 
whether their implementation of these guidelines is 
effective in controlling hypertension.
One study in which the results support the JNC VI 
guidelines used systematic review and meta-analysis of 
first-line antihypertensive medications for success in 
hypertension control (Psaty et al., 1997). The purpose of 
the study was to examine the efficacy of the four most 
common antihypertensive medication classes in preventing 
the occurrence of myocardial infarction and stroke through 
the control of hypertension.
Eighteen randomized clinical trials were found for 
analysis in the study by using MEDLINE and previous meta­
analysis (Psaty et al., 1997). The patients (N = 48,220) 
included in these studies were from the United States, 
Europe, Scandinavia, Australia, and Japan.
The patients were followed for an average of 5 years 
in the studies. The patients were all middle-aged to 
elderly, and a few of the patients in various studies had 
"very high blood pressure or . . . survived a stroke"
(Psaty et al., 1997, p. 740). The randomized trials were 
limited to trials which were "at least 1 year long, 
placebo controlled, and unconfounded by other therapies 
. . . we excluded multiple risk factor intervention trials
and trials using first-line agents other than [diuretics.
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B-blockers, calcium channel blockers, and ACE inhibitors]" 
(Psaty et al., 1997, p. 740). The authors stated no trials 
that evaluated calcium channel blockers and ACE inhibitors 
were found in regard to the criteria, so all 18 trials 
were related to diuretics and B-blockers and were all 
previously used in a meta-analysis study. Data for the 
study were gathered by Psaty and Nichols and "differences 
were resolved by consensus" (Psaty et al., 1997, p. 740).
The clinical trials in the study were classified into 
three treatment strategies, as follows : "(1) high-dose 
diuretic therapy . . . doses greater than or equal to the
equivalent of 50 mg of chlorthalidone or 
hydrochlorothiazide (HCTZ), (2) low-dose diuretic . . .
the equivalent of 12.5 to 25 mg per day of chlorthalidone 
or HCTZ, and (3) B-blocker therapy" (Psaty et al., 1997, 
p. 740). The ACE inhibitor and calcium channel blocker 
trials were selected from "the largest and longest trials 
evaluating surrogate endpoints . . . for the special
indicators [of myocardial infraction and stroke] we relied 
upon recent meta-analysis" (Psaty et al., 1997, p. 740).
All three treatment strategies of high-dose 
diuretics, low-dose diuretics, and B-blocker decreased the 
incidence of stroke in patients who had hypertension with 
relative risks (RR) of .49, 0.66, and 0.71, respectively. 
The occurrence of stroke with the high-dose diuretics was
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significantly different from the use of B-blocker therapy 
(p = .02), but was not significant in comparison to the 
low-dose diuretic therapy. In regard to coronary artery 
disease, which is a precursor to myocardial infarction, 
high-dose diuretic therapy and B-blocker therapy had 
similar RR of 0.99 and 0.93, but did not produce results 
significantly different from the placebo. Low-dose 
diuretic therapy, on the other hand, was significant in 
its ability to reduce coronary artery disease when 
compared to the other two strategies mentioned with an RR 
of 0.72 and a statistical significance to B-blockers of p 
= .03 and high-dose diuretics (p = .01) (Psaty et al.,
1997).
Compelling clinical trials for ACE inhibitors and 
calcium channel blockers were discussed by the author, but 
no meta-analysis was performed due to a lack of long-term 
trials. Instead, the authors reviewed various clinical 
trials in support of certain antihypertensives as first- 
line therapy in specific populations as recommended by the 
JNC VI guidelines for hypertension treatment. Alarming 
information on Nifedipine and short-acting calcium channel 
blockers was discussed by the authors. In six clinical 
trials concerning the calcium channel blocker. Nifedipine, 
at a dose of 80 mg or more per day there was an increased 
RR of mortality (2.64, 95% Cl, 1.42 - 4.92) associated
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with the therapy (Psaty et al., 1997). Also, in the
Seattle, Washington, case-control study mentioned by the
author, "short-acting calcium channel blockers were
associated with an increased risk of myocardial infarction
. . . than beta-blockers [in] subjects with or without CVD
(risk ratio, 1.57; 95% Cl, 1.24 - 2.04; p < .001)" (Psaty
et al., 1997, p. 743). One meta-analysis study on ACE
inhibitors' effect on reducing mortality in patients with
congestive heart failure was reviewed by the author. Psaty
et al. stated, "In the meta-analysis by Garg and
colleagues, the RR for total mortality was 0.77 (95% Cl,
0.58 - 0.83), and the reduction was primarily due to fewer
deaths from progressive heart failure (RR, 0.69, 95% Cl,
0.58 - 0.83)" (p. 742).
Although the authors did not do a meta-analysis of
data for ACE inhibitors and calcium channel blocker
clinical trials reviewed, they make a strong statement in
favor of diuretics and beta-blockers rather than these
newer antihypertensives due to a lack of long-term
controlled clinical trials toward various and end-points
of cardiovascular disease prevention or progression. Psaty
et al. supported diuretics and beta-blockers as first-line
therapy by stating that.
Diuretics and B-blockers--inexpensive 
antihypertensive agents— have been proven both 
safe and effective in long-term trials . . . the
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clinical rationale for withholding safe, 
effective, and proven therapies must be 
compelling . . . the potential benefit of a
surrogate end point or a laboratory value must 
be weighed thoughtfully against the known health 
risks of withholding the proven first-line 
therapies currently recommended by the JNC-V.
(Psaty et al., 1997, p. 744)
These findings supported the JNC VI guidelines that were
published in the same year, as diuretics and beta-blockers
were still recommended as first-line treatments for
hypertension.
Another study found in the review of literature
supported the JNC VI recommendations to control blood
pressure of patients with hypertension to a level < 140/90
mmHg. The Hypertension Optimal Treatment (HOT) randomized
trial sought to ascertain the association of intensive
blood pressure lowering regimens and cardiovascular
complications in hypertensive patients (Hansson et al.,
1998). The study wanted to see if there was a correlation
between lower diastolic blood pressure readings over time
and subsequent cardiovascular events.
The study was a randomized trial composed of 18,790
patients from 26 different countries. The patients were 50
to 80 years in age, with a mean age of 61.5 years. Each
person in the sample was randomly assigned to a target
diastolic blood pressure level of < 90 mmHg, < 85 mmHg, or
equal to 80 mmHg in the study in which half received
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acetylsalicylic acid (ASA) and the other half placebo 
(Hansson et al., 1998). The countries for the study were 
selected from the following four continents: North 
America, South America, Europe, and Asia. The sample was 
followed up for cardiovascular events for an average of 
3.8 years (range 3.3 - 4.9) (Hansson et al., 1998).
Patients were treated in one of five different modes 
to obtain the diastolic blood pressure level desired as 
follows: Step 1: felodipine (calcium channel blocker) 5 mg 
a day. Step 2: ACE inhibitor or beta-blocker added to step 
1, Step 3: titration of the dosage of felodipine to 10 mg 
a day with ACE inhibitor or beta-blocker. Step 4: doubling 
the dosage of ACE inhibitor or beta-blocker in Step 2 with 
felodipine, and Step 5: adding a diuretic to ACE 
inhibitor/beta-blocker and felodipine therapy in Step 4 
(Hansson et al., 1998). Blood pressure measurements were 
measured using, "an oscillometric semi-automatic device 
(Visomat OZ, D2, International, Hestia, Germany)" (Hansson 
et al., 1998, p. 1756). The validity and accuracy of the 
machine to measure blood pressures were "subjected to the 
blood-pressure-measuring equipment proposed by the British 
Hypertension Society and was found to meet those stringent 
criteria" (Hansson et al., 1998, p. 1757).
For the purpose of the study, major cardiovascular 
events were described as "fatal and non-fatal myocardial
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infarction (MI), all strokes and all other cardiovascular
death" (Hansson et al., 1998, p. 1756). Reported events
were gathered from hospital and physician records, death
certificates, and N. reports. Fatal events were described
as death that occurred within 28 days of onset of a
cardiovascular event. Silent Mis were also evaluated for
and were classified as a change of a new Q wave or QS
waves from a baseline ECG reading without the patient
portraying any signs or symptoms.
The study used a Poisson model to analyze the trends
of CV events between the different groups with assigned
target blood pressures. Hansson and colleagues stated.
The logarithm of the hazard rate was modeled as 
a continuous function of mean blood pressure by 
connected linear and quadratic pieces in 
specified intervals . . . time dependent
information was used for the covariants current 
age, time from entry and blood pressure frame 
every 6 months . . . two-tailed tests were used.
(p. 1757)
The researchers found that the patients who 
participated in one of the five antihypertensive treatment 
regimens had a reduction in their systolic and diastolic 
blood pressure. The antihypertensive regimens reduced the 
average diastolic blood pressure (DBP) by 20.3 mmHg, 22.3 
mmHg, and 24.3 mmHg and the average systolic blood 
pressure (SBP) by 26.2 mmHg, 28.0 mmHg, and 29.9 mmHg in 
the targeted DBP groups of < 90 mmHg, < 85 mmHg, and < 8 0
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mmHg;. respectively, when compared to DBF levels at 
baseline (Hansson et al., 1998) . There were very few 
patients in the study with a DBF > 90 mmHg after receiving 
antihypertensive treatment. Only 12%, 7%, and 6% of the 
target group of < 90 mmHg, < 85 mmHg, and < 80 mmHg had 
DBF greater than 90 mmHg following treatment. The patients 
receiving Aspirin (ASA) therapy did not have a 
significantly different average blood pressure reading 
than those who did not (142/83.2 mmHg vs. 141.4/82.9 
mmHg). Fatients whose diastolic blood pressure (DBF) was 
controlled to < 85 mmHg and < 80 mmHg had significantly 
reduced risks of certain cardiovascular (CV) events when 
compared to the group assigned a target blood pressure of 
< 90 mmHg. The events of all Mis were found to be reduced 
by 25% in the group with a target DBF of < 85 mmHg and by 
28% in the group with a target DBF of < 80 mmHg when 
compared with the patients in the target DBF group of < 90 
mmHg.
Diabetic patients had a marked reduction of CV events 
in the group of < 80 mmHg when compared to the group of < 
90 mmHg as target DBFs. In 1,501 of the patients with 
diabetes mellitus, the risk of a major CV was found to be 
50% less in the < 80 mmHg DBF group than those in the < 90 
mmHg group. The event of stroke in the diabetic patients 
was also reduced in the target group with target DBF of
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< 8 0 mmHg by 30% when compared to the < 90 mmHg group 
(Hansson et al., 1998).
Another significant finding in the study was the 
reduction in the incidence of stroke in patients with 
previous ischemic heart disease with a 43% reduction in 
the DBF target group of < 80 mmHg versus the DBF target 
group of < 90 mmHg. It is important to note that the 
average DBF after treatment in the < 80 mmHg group was not
< 80 mmHg but 81.1 mmHg ( ^  = 5.3) following 
antihypertensive treatment. The average DBF of the < 90 
mmHg group and < 85 mmHg group after treatment was 85.2 
mmHg (S^ = 5.1) and 83.2 (S_D = 4.8), respectively.
In conclusion, Hansson and colleagues asserted,
"intensive lowering of blood pressure in patients with
hypertension was associated with a low rate of
cardiovascular events . . . the HOT study shows the
benefit of lowering the DBF down to 82.6 mmHg" (1998, p.
1755). These findings support the JNC VI guidelines which
recommend that health care providers control their
hypertensive patients' blood pressure to < 140/90 in
patients without target organ disease and < 130/85 mmHg in
patients with diabetes. The JNC VI guidelines state that.
The goal of prevention and management of 
hypertension is to reduce morbidity and 
mortality by the least intrusive means possible 
. . . this may be accomplished by achieving and
maintaining systolic blood pressure below 140
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mmHg and DBF below 90 mmHg and lower if
tolerated. (JNC VI, 1997, p. 19)
The results also support the JNC VI recommendation for 
more aggressive treatment of hypertension in the elderly 
to prevent fatal CV events, as many of the patients were > 
65 years of age with an average age of 61.5 years (Range: 
50 to 80).
Staessen et al. (2000) asserted that the results of 
their study supported the JNC VI guidelines concerning the 
treatment of systolic blood pressure to a level to prevent 
target organ damage (Staessen et al., 1998). These 
researchers were interested in the outcomes of treated and 
untreated isolated systolic hypertensive patients. The 
study was a meta-analysis study that focused on outcome 
trials concerning isolated systolic hypertension (ISH) and 
subsequent associated risks.
The sample of patients to be analyzed in the meta­
analysis was formed samples from eight total trials 
reviewed. Three studies were outcome trials directly 
related to ISH. The five other trials were outcome-based 
hypertension trials that included ISH patients as a 
subgroup. A total of 15,693 patients from the eight 
clinical trials were included in the meta-analysis group. 
The majority of the patients in the study, excluding the 
China trial, were female and had an average age of 70
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years (Range: 60 to 760). Smokers composed 15.8% of the 
sample, and 30.9% of the sample had one or more 
cardiovascular complications before their individual trial 
began. Concerning those patients with previous 
cardiovascular disease or complications, 4.5% had a 
stroke, 7.4% had a myocardial infarction (MI), 14.2% had 
symptoms of angina, and 33% had ECG changes that were 
indicative of left ventricular hypertrophy (Staessen et 
al., 1998).
These authors defined ISH as a systolic blood 
pressure > 160 mmHg with a diastolic pressure of < 95 
mmHg. The outcome criteria that were evaluated for 
regarding their association with ISH were as follows: (a)
total and cardiovascular mortality, (b) cardiovascular 
complications, (c) stroke, and (d) coronary events 
(Staessen et al., 2000).
In analysis of the eight different outcome trials 
concerning ISH, the researchers used "nonparametric 
methods and Cox regression to model the risks associated 
with blood pressure and to correct for regression dilution 
bias" (Staessen et al., 2000, p. 865). Various 
antihypertensive drug regimens were used in each trial 
analyzed to reach target blood pressures and all trials 
were controlled. In the Cox regression statistical method, 
used by the researchers, age, sex, and systolic and
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diastolic blood pressures at baseline were explanatory 
variables. Correction for regression dilution bias was 
estimated by the researchers using a "cohort of patients 
randomized to no treatment who accumulated an event free 
survival for two years" (Staessen et al., 2000, p. 866). 
The researchers "calculated relative benefit as the 
percentage reduction in the outcome rates in the active 
treatment group compared with the rate in the control 
groups . . . absolute benefit with [a] 95% Cl" (Staessen
et al., 2000, p. 866).
The researchers found a reduction of overall 
mortality and cardiovascular events. One significant 
result was the risk of total mortality associated with ISH 
was less than that of diastolic hypertension at the 
beginning of the trial before a treatment plan was started 
(£ = .001 vs. £ = .05, respectively). Analysis of the four 
outcomes, previously stated, after pharmacologic treatment 
with antihypertensives was significant as well. There was 
a 13% (2-22, £ = .02) reduction in total mortality in
patients with a treated systolic blood pressure (SBP) 
level < 160 mmHg when compared to the control group and an 
18% (4-29, £ = .01) reduction in cardiovascular related
death. Patients, in the trials treated to a SBP < 160 
mmHg, also produced a total pooled result of a 26% (17-34,
£ < .001) reduction in cardiovascular complications, a 30%
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(18-41, £ < .001) reduction of stroke, and a 23% (10-34, £
= .001) reduction in coronary events when compared to the
control group (Staessen et al., 2000).
Staessen and colleagues stated after interpretation
of the results that, "Drug treatment is justified in older
patients with isolated systolic hypertension where
systolic blood pressure is 160 mmHg or higher" (Staessen
et al., 2000, p. 872). This study's results and
interpretations support the JNC VI guidelines published in
1997 which support a more aggressive treatment of
hypertension in elderly patients to reduce subsequent
cardiovascular mortality and target organ disease. The
study provided significant results that support previous
research that a treatment regimen to reduce ISH reduces
the risk for cardiovascular mortality and events as
recommended by the JNC VI guidelines which affirms
The goal of treatment in older patients should 
be the same as in younger patients (to below 
140/90 mmHg if at all possible), although an 
interim goal of systolic blood pressure below 
160 mmHg may be necessary in those patients with 
marked systolic hypertension. (JNC VI, 1997, p.
46)
Another clinical trial supports the JNC VI guidelines 
in regard to its special recommendation to use ACE 
inhibitors to treat hypertension in diabetic patients. The 
clinical trial performed by Morgenson studied the effects 
of the ACE inhibitor lisinopril and Candesartan on the
49
outcome variables of blood pressure and microalbuminuria 
(Morgenson, 2000).
The clinical trial, a prospective, randomized, 
parallel group, double blind study, was performed in 37 
hospitals/primary care centers in Australia, Denmark, 
Finland, and Israel (Morgenson, 2000). The population from 
which the sample was chosen was type 2 diabetics who had 
previously been diagnosed with hypertension and 
microalbuminuria. The sample was composed of 199 type 2 
diabetics with a mean age of 60 years (Range: 30-75) and 
had the following criteria: (a) urinary albumin :
creatinine ratio of 2.5 - 25 mcg/mmol after 2 weeks of 
placebo treatment and (b) a diastolic blood pressure of 90 
- 110 mmHg following both 2 and 4 weeks of placebo 
treatment (Morgenson, 2000). Two patients were excluded 
from the study due to refusal to take treatment regimen 
leaving 197 patients who actively received treatment. 
Criteria used to exclude people during the sampling 
process were as follows: (a) a body mass index (BMI) of >
40 kg/m2, (b) a systolic blood pressure > 200 mmHg, (c) a 
non-diabetic cause of secondary hypertension, (d) a serum 
creatinine level of 130 x 6 dmol/L in women and 150 x 6 
dmol/L in men, (e) a serum potassium level > 5.5 mmol/L,
(f) a hemoglobin Â  ̂ of greater than 10%, (g) potential or
actual pregnancy, and (h) patient breast-feeding
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(Morgenson, 2000, p. 1442). Patients taking lisinopril 
only during the study were by majority male (N = 62) 
compared to women (N = 36) and had a mean BMI of 2 9.8 
kg/m2, a mean systolic blood pressure of 162.6 mmHg ( ^  = 
17.6), and a mean diastolic blood pressure of 95.7 mmHg 
(SD = 6.2 mmHg) before treatment. The patients, on 
average, had been diabetics for 8.4 years ( ^  = 7.3) and 
hypertensive for 9.0 years (SD = 8.9). These patients also 
had a mean urinary albumin : creatinine ratio of 6.6 
mcg/mmol (^D = 1.1) and a mean hemoglobin of 7.6% (SD = 
1.6%). Fourteen of the 197 randomized patients who 
underwent active treatment dropped out due to bothersome 
side effects, with the main adverse side effects of 
dizziness, feeling weak, or both (Morgenson, 2000).
The methods of the study included an antihypertensive 
regimen of either lisinopril, Candesartan, or combination 
over 24 weeks while evaluating each regimen's effect on 
the outcome criteria of hypertension and microalbuminuria. 
Baseline hypertension levels and urinary 
albumin : creatinine ratios were drawn and evaluated and 
evaluated again at 12 weeks and 24 weeks post-treatment.
The post-placebo/treatment phase consisted of two phases 
of treatment. In the first phase of treatment the sample 
was divided into two groups. The first group received 
lisinopril treatment only for 12 weeks and the second
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group, Candesartan, for 12 weeks. The second phase of the 
treatment regimen lasted from the 12̂  ̂ week to the 24^^ 
week and split the sample into three groups. The first 
group was treated with lisinopril only. The second group 
was treated with Candesartan only. The third group was 
treated with a combination of lisinopril and Candesartan 
as long as the patient had a diastolic blood pressure > 80 
mmHg at 12 weeks following their previous treatment 
regimen. The daily dose of Candesartan used was 16 mg, and 
the daily dose of lisinopril was 20 mg.
Blood pressure measurements were taken in the arm 
with each patient resting for 5 minutes at approximately 
24 hours post-treatment with antihypertensive medicine. An 
automated blood pressure machine was used to take 
measurements. Three blood pressure measurements were taken 
sitting and averaged and then one measurement after 
standing for 1 min. A total of nine blood pressure 
measurement sessions were performed during the study.
Three sessions were conducted before treatment to produce 
an established baseline blood pressure.
Microalbuminuria was measured through urinary 
albumin : creatinine ratios. The urine samples used for 
ratios were spot samples taken on two consecutive days by 
the patients in the morning and brought to the clinic 
where serum creatinine levels were drawn. These
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microalbuminuria results were performed before treatment 
as a baseline measurement and then reevaluated at 12 and 
24 weeks. Urinalysis, hematology, and hemoglobin 
measurements also were taken at baseline, 12 weeks, and 24 
weeks.
The researchers used a linear model for analysis of 
covariance when averaging the change of microalbuminuria 
from baseline at 12 weeks and 24 weeks (Morgenson, 2000). 
The analysis of covariance used "factors for treatment, 
centre, and interaction between them . . . changes in
diastolic blood pressure and body weight . . .  as 
covariates" (Morgenson, 2000, p. 1442). The results were 
shown as "estimates of the true geometric means and as 
estimates of ratios of the true geometric means, with 
their 95% confidence intervals and corresponding £ values" 
(Morgenson, 2000, p. 1442).
Patients treated with lisinopril only achieved a 9.7% 
(7.9 - 11.5, £ < .0001) reduction in sitting diastolic 
pressure, a 15.7% (12.2 - 19.2, £ < .001) reduction in 
sitting systolic pressure, and a 46% (35 - 56, £ < .001) 
reduction in microalbuminuria at 12 weeks post-treatment 
with a 20-mg daily dose. Outcomes at 24 weeks were also 
significant with a 10.7% (8 - 13.5, £ < .001) reduction in 
sitting diastolic blood pressure, a 16.7% (11.4 - 21.9, £
< .001) reduction in sitting systolic blood pressure, and
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a 39% (20 - 54, £ < .001) reduction microalbuminuria. The 
researcher stated that the best results for the study came 
from patients receiving the combination therapy of 
Candesartan and lisinopril but were not reproduced here 
due to Candesartan not being an ACE inhibitor and 
therefore not recommended by the JNC VI recommendations 
which concluded that, "in patients with diabetic 
nephropathy ACE inhibitors are preferred" (NHLBI, 1997, p. 
49) .
The author concluded that.
Recent guidelines for blood pressure targets in 
diabetic patients have emphasized the importance 
of aggressive blood pressure reduction in 
diabetic patients with evidence of renal disease 
. . . our results show that dual blockade of
renin-angiotensin system particularly effective 
in decreasing blood pressure in these patients 
and supports this . . . therapeutic approach for
the prevention of diabetic renal and vascular 
disorders. (Morgenson, 2001, p. 1444)
Lisinopril treatment alone, however, was also very
effective in its blockage of the renin-angiotensin system
and produced significant effects in decreasing
hypertension microalbuminuria. This study further supports
the studies reviewed by the JNC VI which recommended ACE
inhibitors as the preferred treatment regimen for diabetic
hypertensive patients to prevent future cardiovascular
disease and diabetic complications such as nephropathy.
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Although the review of the literature was not 
exhaustive in nature, it is sufficient in its ability to 
support a need for further dissemination of the JNC VI 
guidelines. It also supports the need for further research 
for compliance with these guidelines in the future. The 
recently published studies reviewed here further support 
the validity of the research-based JNC VI guidelines 
published in 1997. The review of literature chosen for 
this study was chosen by the researcher for strength to 
support the JNC VI guidelines and ability to support the 
tool used for measuring compliance with the JNC VI 
guidelines in this study.
Chapter III 
The Method
This researcher was concerned with evaluating primary 
care nurse practitioners' (PCNPs) compliance with the JNC 
VI guidelines in the management of hypertension and will 
be used to formulate strategies to increase compliance 
with theses guidelines in the future to ensure evidence- 
based medicine in the treatment of this national health 
concern.
Design of the Study
The researcher used a descriptive design to define 
the implementation of the sixth edition of the Joint 
National Committee guidelines (JNC VI) for hypertension 
management in practice. A descriptive design was 
appropriate because its focus is on "the frequency of 
occurrence" in variables and does not seek to form 
relationships between variables (Polit & Hungler, 1999, p. 
196). This researcher sought data for explaining PCNPs' 
use of the guidelines established by the JNC VI, and not 
to determine any relationship to actual blood pressure 
readings as an evaluation of hypertension management.
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These data were easily analyzed and disseminated back to 
PCNPs in practice with this design and was considered 
important to the researcher so PCNPs could critique their 
hypertension management strategies in an effective and 
timely manner.
Setting, Population, and Sample
Setting. The settings for the study were various 
outpatient, primary care practice sites within the states 
of Mississippi, Alabama, Tennessee, and Louisiana. Each 
primary care practice had at least one PCNP who treated on 
average at least 5 hypertensive patients per day. Sites 
were obtained by assessing the qualifications of each PCNP 
through a self-report survey included in the study. Sites 
that were reported were as follows: (a) hospital clinic,
(b) free clinic, (c) health department, and (d) private 
practice.
Population. The population for the study were 
advanced practice nurses, who were licensed and certified 
in the states of Mississippi to practice in the role of an 
PCNP. The PCNPs were experienced in treating adult 
hypertensive patients, had at least 1 year of experience 
as a family nurse practitioner (FNP) or advanced practice 
nurse (ANP), and worked in outpatient settings as a 
primary care provider in the states of Alabama, Louisiana,
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Tennessee, and Mississippi. The specific population from 
which the sample was drawn was a database of FNPs and ANPs 
certified within the state of Mississippi containing over 
600 names of PCNPs. For subjects to be included in the 
study they had to see and treat, on average, a minimum of 
at least 5 hypertensive patients per day and was assessed 
for by self-report.
Sample. The sample for the study was achieved using a 
systematic random sampling design until 200 prospective 
subjects were garnered. The sample was selected from an NP 
database obtained from the Mississippi Board of Nursing as 
the sampling frame by using a computer-generated table of 
random numbers. PCNPs who did not work in an outpatient 
setting or see at least 5 hypertensive patients per day 
were excluded from the sample when data were returned by 
assessing this criteria on a self-reported demographic 
data sheet returned by mail. The final sample included 
those subjects who met the criteria and returned Cagle's 
JNC VI Guidelines Compliance Survey (see Appendix A) to be 
included in the study.
Instrumentation
Cagle's JNC VI Guidelines Compliance Survey was used 
to assess the PCNPs' implementation of the JNC VI 
guidelines in practice. The tool was vignettes developed
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by the researcher to evaluate PCNPs' beliefs, knowledge, 
and practices in hypertension care, especially 
hypertension management strategies that are recommended by 
the JNC VI. These vignettes were case studies about 
hypertension management situations that included patients 
with varying co-morbidity. The vignettes focused on both 
essential hypertension and hypertension that could be 
secondary to disease process. The vignettes were developed 
to evaluate PCNPs' treatment practices by having the PCNPs 
write out interventions for each case study in three 
areas: (a) pharmacologic, (b) non-pharmacologic, and (c)
labs and procedures that could be ordered by the FNP in 
the management of hypertension. The labs or procedures 
(area c) could be checked if the PCNP believed they were 
needed and there was a space for the PCNPs to write in any 
labs or procedures that they felt would be necessary in 
managing the patient's hypertension. All labs and 
procedures that are recommended by the JNC VI guidelines 
for each case study were provided as a choice along with 
other tests that are not recommended.
Ten critical factors, JNC VI guidelines 
recommendations, were identified and chosen as essential 
for competent hypertension management practice for the 
areas of (a), (b), and (c). Scoring of the vignettes were
performed by evaluating the frequency of JNC VI guidelines
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interventions chosen or written in by the PCNPs in regard
to each case study.
The second case study was scored by giving one point
in the pharmacologic area for starting this patient on an
ACE inhibitor, ACE inhibitor plus diuretic, or increasing
the dose of her hydrochlorothiazide (HCTZ) due to the
patient's past history of left-sided heart enlargement
(probably left ventricular hypertrophy) and supporting
symptoms of shortness of breath with activity. Beta-
blockers are contraindicated due to her history of COPD,
and calcium channel blockers are not as effective in
preventing the occurrence of congestive heart failure like
ACE inhibitors. The JNC VI (NHLBI, 1997) guidelines state.
Some patients with hypertension (current or 
past) develop heart failure with a normal 
ejection fraction, implying diastolic 
dysfunction . . . the Framingham Heart Study
have demonstrated that hypertension continues to 
be the major cause of left ventricular failure .
. . dihydropyridine calcium antagonists [Lotrel]
and Felodipine have been demonstrated to be safe 
in treating angina and hypertension in patients 
with advanced left ventricular dysfunction when 
used in addition to ACE inhibitors, diuretic, or 
digoxin . . . other calcium antagonists are not
recommended in these patients, (p. 47)
One point was awarded in the non-pharmacologic area
if lifestyle modifications were addressed including at
least counseling on a healthy heart diet. One point was
awarded in the diagnostic tests/lab area if the PCNP
ordered at least the following tests: urinalysis.
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electrolytes, EKG, and a lipid profile. The JNC VI 
guidelines recommend limited echocardiography in patients 
with LVH due to cost and an EKG can detect its presence. 
The PCNPs were not penalized for ordering an 
echocardiogram (Echo) due to the patient's complaints of 
shortness of breath and 3 years since last Echo. Although, 
requesting the old echo and a full cardiovascular 
examination may eliminate the need due to no shortness of 
breath at rest and would surely benefit this grandmother 
on Medicaid by saving her the money of an unwarranted 
Echo. The PCNPs were not penalized for not including a 
urinalysis as long as they spoke to getting electrolytes 
with BUN/creatinine or similar profile. Other tests may 
have been warranted and ordered to help with the clinical 
picture, but the diagnostic tests/labs chosen were 
considered critical test/labs to be ordered due to this 
patient being on a diuretic. Also, this patient needed her 
renal function checked before starting an ACE inhibitor, 
an EKG to confirm LVH and rule out any myocardial
infarction, and a lipid profile to assess for
hyperlipidemia as a future MI risk factor that can be
controlled. All of these tests are recommended as routine
tests to be run before starting antihypertensive 
pharmacologic treatment by the JNC VI (NHLBI, 1997).
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The third and last case study was scored by giving
one point in the pharmacologic area for the following : (a)
changing the patient to another ACE, (b) change to another
ACE 4- diuretic, (c) change to Angiotensin II receptor
antagonist, or (d) placing the patient on a calcium
antagonist plus ACE inhibitor. The main result to achieve
in this patient and gain a point was renoprotection. The
JNC VI guidelines state that ACE inhibitors are the
preferred antihypertensive agent for diabetics to prevent
diabetic nephropathy and for this reason should not be
removed from this patient even though other medicines
offer some renoprotection. ACE inhibitors also may have a
favorable effect on patients with the co-morbid condition
of renal insufficiency, which is a possibility with this
noncompliant African American diabetic whose blood sugar
and diet are uncontrolled. The patient has a family
history of renal failure and has symptoms of polyuria
which, although is probably related to his diabetes, is
also a symptom of acute renal failure/insufficiency. The
JNC VI states.
Hypertensive nephrosclerosis is among the most 
common causes of progressive renal disease, 
particularly in African Americans . . .
impressive results have been achieved with ACE 
inhibitors with type 1 diabetic nephropathy, in 
patients with proteinuria greater than 1 gm in 
24 hours, and in patients with renal 
insufficiency . . . consequently, patients with
hypertension who have renal insufficiency should
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receive, unless contraindicated, an ACE 
inhibitor in most cases, along with a diuretic 
to control hypertension and slow progressive 
renal failure. (NHLBI, 1997, p. 48)
Calcium channel blockers by themselves and beta-blockers
were considered to be inadequate treatment due to JNC VI
recommendations.
Consideration was given on whether or not to include
long-acting, once-daily-dosing as criteria to receive the
point in this category, but was eliminated due to the
alteration in response that was expected in return of the
survey. The researcher would have had difficulty
ascertaining if once-daily-dosing was implied with
medication change or combination agents and specific
instructions on prescription were not given to guide this
response.
The nonpharmacologic area was scored by receiving one
half point for the following interventions : tobacco
cessation and alcohol moderation. One point was received
for diet modification that included a low-sodium diet (< 3
g/day). The JNC VI asserts that.
Excessive alcohol intake is an important risk 
factor for high blood pressure, can cause 
resistance to antihypertensive therapy and is a 
risk factor for stroke . . . alcohol should be
[limited daily to] no more than 1 ounce of 
ethanol . . . or 2 ounces of 100 proof whiskey .
. . such amounts do not raise blood pressure and
have been associated with a lower risk of CHD.
(p. 21)
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The JNC VI als© states that,
African Americans, -older people, and patients 
with hypertension or diabetes are more sensitive 
to changes in dietary sodium chloride . . .
meta-analysis of clinical trials reveals that a 
reduction of 75 to 100 mmol in sodium intake 
lowers blood pressure over periods of several 
weeks to a few years . . . [and one meta­
analysis found that] patients age 45 or older 
with hypertension found an average decrease of 
6.3/2.2 mmHg with a urinary sodium reduction of 
95 mmol per day. (p. 21)
Concerning the tobacco cessation intervention, the 
JNC VI states that, "Cigarette smoking is a powerful risk 
factor for cardiovascular disease, and avoidance of 
tobacco in any form is essential . . . the cardiovascular
benefits of discontinuing tobacco use can be seen within a 
year in all age groups" (NHLBI, 1997, p. 23). These JNC VI 
recommendations are critical factors for this African 
American patient who binge drinks on the weekends, smokes, 
and seems to be noncompliant with his diabetic diet and 
treatment regimen.
The diagnostic/labs intervention area was scored by 
awarding 1 point for ordering the following tests/labs : 
urinalysis, fasting glucose, lipid profile, 24-hour urine 
protein/creatinine clearance, electrolytes, and EKG. PCNPs 
were not penalized for not ordering a fasting blood sugar 
if they ordered an HgbA^c or a metabolic profile which 
included a serum glucose. These are better tests to 
measure diabetic compliance than a fasting blood sugar.
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The PCNPs also were not penalized for not ordering a 24- 
hour urine if they spoke to assessing the urinalysis 
first, ordered an electrolyte profile with BUN/creatinine, 
or ordered a 24-hour urine for microalbuminuria. These 
tests were considered critical labs to order for this 
patient due to his presentation and medical and family 
history.
The vignettes were assumed to have face value 
validity in assessing PCNPs' use of JNC VI guidelines in 
practice as agreed upon by the researcher and three other 
FNPs with hypertension management education. The FNPs 
chosen for peer review of the vignettes for content 
validity each had over 5 years of experience as an FNP and 
were familiar with the JNC VI guidelines. The vignettes 
were peer reviewed for readability and comprehension by 
the FNPs previously mentioned and 28 FNP students at the 
Mississippi University for Women.
Methods of Data Collection
The research study proposal was first submitted for 
approval by the Mississippi University for Women's 
Committee on Use of Human Subjects in Experimentation to 
gain acceptance of the study in regard to confidentiality 
and beneficence to participants and the overall benefits 
and risks (see Appendix B). Following approval, the
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database/PCNP list was secured from the Mississippi Board 
of Nursing. After obtaining an adequate random sample of 
200 PCNPs for the study, a point of contact for each PCNP 
was established via the database used in the sampling 
process. Each prospective participant was sent a packet 
including a cover letter (see Appendix C) describing the 
study and the Cagle's JNC VI Guidelines Compliance Survey 
and a self-addressed, stamped envelope. Each prospective 
PCNP was informed that return of the survey included would 
imply consent to participate in the study. Each cover 
letter also included the researcher's address, telephone 
number, and e-mail address so each PCNP could have access 
to the researcher for any questions regarding the study.
Two weeks following the first mailing, a second 
correspondence was sent including a reminder letter for 
participation (see Appendix D). An additional question was 
sent following the second mailing on a self-addressed, 
stamped postcard (see Appendix E). The final question was 
as follows : Are you aware of the current national 
guidelines (JNC VI) for hypertension management? This 
question was used to assess awareness and need for further 
dissemination of the JNC VI guidelines to PCNPs in 
practice and insight as possible explanation for some PCNP 
noncompliance with the JNC VI guidelines. The question was 
mailed with the last survey and was returned with a self­
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addressed, stamped envelope. The participants were 
informed to return mailings without their name or address 
to ensure confidentiality.
These data were analyzed using descriptive statistics 
and disseminated back to PCNPs who participated in the 
study at their discretion. Information on how to obtain 
the results of the study and the JNC VI guidelines was 
made available to the PCNPs who participated in the study 
at their request by contacting the researcher via phone or 
E-mail.
Data Analysis
Data returned from the vignettes, as provided by the 
PCNPs in the study, were analyzed using univariate 
descriptive statistics, such as frequency distribution of 
scores and the variability of individual scores in the 
form of range and standard deviation. There were 10 
critical factors/JNC VI guidelines to be measured by the 
vignettes provided to the PCNPs in the study. Each 
critical factor received a score of +1 if written in or 
chosen as an intervention with 0 being the lowest 
individual score obtainable and 10 being the highest. The 
group mean score of all the PCNPs multiplied by the number 
of PCNPs in the study (N = 200) was obtained and divided 
by the total best possible score of 2,000 to elicit a
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percentile grade for the sample. The best case percentile 
score and worst case percentile score also were reported. 
The FNPs were required to get all critical factors correct 
for each case study to be considered completely compliant 
in implementing JNC VI guidelines for the particular case 
study and a minimum of two to three critical factors for 
each case study to be considered partially compliant. This 
equaled an overall score of 10 for participants who were 
considered completely compliant with JNC VI guidelines and 
a score of 7 to 9 considered partially compliant. Any 
score of less than 2 critical factors for one individual 
case or an overall survey score of less than 7 was 
evaluated as noncompliance with the JNC VI guidelines in 
treatment. The number of PCNPs who fell into each category 
of compliant, partially compliant, or noncompliant were 
reported in number and as a percentile of the total sample 
for each case study and the total study. Finally, the 
range between the lowest individual score and the highest 
individual score, along with a measurement of standard 
deviation in scores, were obtained to show the degree of 
homogeneity in scores. This procedure was used to assess 
the validity of the survey in producing scores that would 
implicate a high degree of homogeneity in comprehension 
and use of the survey to provide data for the study.
Results were checked for accuracy by a research committee
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and were provided in both narrative form and in the form 
of tables to enhance comprehension of the data by 
consumers of the research in the future.
Chapter IV 
The Findings
This study, which was concerned with primary care 
nurse practitioners' (PCNPs) compliance with the JNC VI 
guidelines in the management of hypertension, used a 
survey method to gather data for analysis. The data 
returned via the Cagle's JNC VI Guidelines Compliance 
Survey were scored using 10 critical factors/JNC guideline 
parameters established for each case study. Three 
points/parameters were allotted for the first two case 
studies and 4 points for the last case study. One 
point/parameter was available for each case study 
intervention area of pharmacologic, non-pharmacologic, and 
diagnostic tests/labs, except for Case #3 which had two 
points available in the non-pharmacologic intervention 
area. Data collection began on May 30, 2001, and ended on 
June 16, 2001. This chapter is focused on PCNPs' 
compliance with JNC VI guidelines and contains the 
demographic, descriptive data concerning the sample and 




Description of the Sample
The Cagle's JNC VI Guidelines Compliance Survey was 
returned by 53 (26.5%) PCNPs out of 200 surveys mailed. Of 
the 53 respondents, 16 (37%) of the PCNPs had to be 
eliminated from participating in the study due to not 
meeting the requirement of treating, on average, at least 
5 hypertensive patients a day. The final sample of PCNPs 
(N = 37) were by majority master's prepared (n = 35,
94.6%) and had < 5 years of experience as a primary care 
practitioner (n = 22, 61.1%). The majority of the PCNPs 
worked in a private practice (n = 24, 64.9%), followed by 
hospital clinics (n = 10, 27%) and free clinics, health 
departments, community clinics (n = 6, 16.2%). The average 
years of experience of the PCNPs was 5.5 years (Range: 1- 
25, SD = 2.1) with only three PCNPs having more than 10 
years of experience.
Results of Data Analysis
A total score of 10 was considered to be compliance 
with the JNC VI guidelines, and a score of 7 to 9 was 
partial compliance. Any score less than 7 was considered 
noncompliance in the use of JNC VI guidelines for treating 
hypertensive patients.
Only 10 (27%) of the 37 PCNPs were partially
compliant with a score of 7 to 9. This left the majority
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of the PCNPs (n = 27, 73%) scoring less than 7 and 
considered noncompliant with the JNC VI recommendation in 
the management of hypertensive patients. The best total 
survey score was 9 (10.8% of the sample scores), and the 
worst total case score was 2 (5.4% of the sample scores).
The total distribution of scores can be seen in Figure 1. 
Since the total average score for the 37 PCNPs in the 
sample was 5.9 (Range: 2-9, = 1.82), the researcher
determined that nurse practitioners (NPs) are more 
compliant with the JNC VI guidelines, therefore are not 
effectively employing them.
Scores
7 10 13 16 19 22 25 28 31 34 37
0  Individual PCNP Scores 
0  Average Total Score 
□  Standard Deviation
Figure 1. Distribution of scores.
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The average total score for PCNPs who worked in a 
private practice setting and worst clinical site score was 
5.6 (Range: 2-9, = 1.90), with only a small number (n =
5, 20.8%) earning a partially compliant score of 7 to 9. 
The average total score for the PCNPs in the hospital 
clinics and best clinical site score was 6.7 (Range: 4-9, 
SD = 1.7), with only 4 (40%) of the PCNPs scoring a 7 or
higher and being compliant. The rest of the clinical sites 
of health departments, community clinics, free clinics, 
and other clinical sites were grouped together due to the 
small number (n = 6). These clinical settings had a total 
average survey score of 5.8 (Range : 5-8, ^  = 1.3), with 2 
(33.3%) of the 6 PCNPs scoring a 7 or higher (see Figures 
2, 3, and 4).
s8CO
1 2 3 4 5 6 7 8 9  10 
PCNPs (1-10)
0  PCNP Scores/Hospital Qinic (PCNPs (1- 10)) 
0  Standard Deviation 
□  Average Total Score
Figure 2 . Clinical Sites - Hospital
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Figure 4. Clinical setting-all other settings
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PCNPs with over 5 years of experience (n = 14, 38.9%) 
scored higher than their peers with < 5 years experience 
(n = 22, 61.1%) with an average total survey score of 6.9 
(Range: 4-9, = 1.5). The less experienced PCNPs with <
5 years of experience as an PCNP had a total average 
survey score of 5.3 (Range : 2-9, SD = 1.8) . The PCNPs with 
more than 5 years of experience were twice as likely to 
obtain a score of competence (n = 6, 42.9%) than their 
less experienced colleagues (n = 4, 18.2%).
The best overall average, case study score was
obtained in Case Study #1, with a score of 2.4 (Range: 1- 
3, ^  = 0.6) and 18 (48.6%) of the PCNPs receiving a score
of a 3 which was considered to be compliant with the JNC 
VI guidelines for the case study. The worst overall, 
average case study score was obtained on Case Study #3, 
with a score of 1.9 (Range: 0-4, ^  = 1.1). A score of a 4 
was needed to be completely compliant with the JNC VI 
guidelines and a score of a 3 for partial compliance. Only 
a few (n = 3, 8.1%) received a score of a 4 and were 
totally compliant with the JNC VI guidelines chosen to 
score the case study. Only 8 (21.6%) received a score of 3
and were partially compliant. The second case study also 
had a high degree of noncompliance with a score of 2 or
less (n = 17, 50%), and the average total score for this
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Only 16 of the PCNPs returned the postcard answering 
the question of whether or not they were aware of the JNC 
VI guidelines. Of these, 12 (75%) stated they were aware
of these guidelines for hypertension management.
Concerning PCNPs' ability to use the JNC VI guidelines in 
anti-hypertensive prescriptive practice, 5 (13.9%) and 18
(50%) of the PCNPs were totally compliant or partially 
compliant with the JNC VI guidelines in the prescription 
of anti-hypertensive medications, respectively, with a 
score of a 2 or a 3 out of 3 in this area leaving 13 (36%)
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Chapter V 
The Outcomes
This study was interested in assessing how well 
primary care nurse practitioners (PCNPs) are managing 
hypertension, as current researchers have indicated that 
many health care providers have not been successfully 
managing hypertension at a level to prevent target organ 
damage over time (Berlowitz et al., 1998; Dustan, 1998; 
Perry et al., 1998; Swales, 1999). As health care 
providers, PCNPs are managing hypertension daily, but 
their compliance to the JNC VI guidelines of hypertension 
management, as a cohort, had not been studied. This study 
was performed to add to this lack of research regarding 
hypertension management by PCNPs.
This researcher sought to answer the two following 
research questions:
1. How effectively are primary care nurse 
practitioners (PCNPs) implementing the JNC VI guidelines 
for hypertension management in practice?
2. Are PCNPs aware of the current national guidelines 
(JNC VI) for hypertension management?
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The Cagle's JNC VI Guidelines Compliance Survey (CJGC 
Survey) and a question concerning PCNPs' awareness of the 
JNC VI guidelines were mailed to 200 prospective 
participants/PCNPs and returned via mail to obtain the 
data necessary to answer these two research questions.
The sample was composed of family nurse 
practitioners (FNPs) and adult nurse practitioners (ANPs) 
with at least one year of experience in hypertension 
treatment who were certified and licensed in the state of 
Mississippi, performing the role of a PCNP, in 
Mississippi, Alabama, Tennessee, or Louisiana. Out of the 
200 CJGC Surveys sent to the 200 prospective PCNPs, 54 
were returned by PCNPs, of which 37 met the criteria for 
inclusion in the study.
The majority of the PCNPs (73%) were noncompliant 
with the JNC VI guidelines in their treatment regimens, 
although they were aware of these guidelines as 
recommendations in the treatment of hypertension. The 
total average score on the CJGC Survey was 5.9 (Range: 2- 
9, SD = 1.82) out of a possible perfect score of 10. The 
minimum score for partial compliance on the CJGC Survey 
was 7 out of 10, with a score of 10 being total compliant. 
Adherence to the JNC VI guidelines was not due to a lack 
of knowledge because 75% (N = 12) of the PCNPs (N = 16)
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reported that they were aware of this most recent edition 
of the JNC VI guidelines of hypertension management.
Discussion
The researcher realized that many things influence an 
PCNP's clinical decision-making skills concerning the 
treatment of the hypertension patient, which could 
possibly affect the PCNPS responses on the CJGC Survey 
toward a score of noncompliance. The survey was not 
labeled as the CJGC Survey as this would have produced 
biased responses. The PCNPs were informed that the case 
studies provided in the survey were being used to assess 
how PCNPs approach hypertension treatment daily without 
regard to any insight that their treatment regimens were 
being reviewed for compliance with the JNC VI guidelines. 
This approach was crucial to prevent unbiased responses. 
The researcher was aware that extraneous circumstances 
could predispose the PCNP to respond to the CJGC Survey in 
a manner that would produce a score of noncompliance 
although the PCNP is aware that the JNC VI guidelines 
exist. These extraneous circumstances are briefly 
discussed here to aid the reader in an accurate and more 
meaningful interpretation of data.
The JNC VI guidelines, although scientifically backed 
and considered to be sound competent management
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recommendations in the treatment of hypertension by 
experts in the field of hypertension management, are just 
recommendations. They are not laws and are not the sole 
measures of competent treatment of hypertension, as the 
clinicians' judgment should be the deciding factor in 
producing a treatment regimen that is based upon the 
assessment of all pertinent health data and history as it 
applies to each individual patient. Saying this, the 
researcher identified three common extraneous variables 
that affect PCNPs clinical decision-making skills daily 
that may have influenced the results of this study.
PCNPs work under protocols for practice in their 
individualized work settings that reduce the ability of 
the PCNPs to have completely independent decision making 
authority over medications and treatment interventions 
prescribed to patients for the treatment of illness. These 
protocols are written by health care organizations to 
simplify and clarify the treatment process for PCNPs to 
efficiently treat illness in a cost-effective manner while 
avoiding legal pitfalls. They are approved and mandated by 
a health care organization's administration to produce 
this desired effect. Due to these restrictions on 
independent clinical decision making, many PCNPs 
habitually treat varying illness by way of protocol. This 
may have affected the responses of some PCNPs who
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responded to Cagle's JNC VI Guidelines Compliance Survey. 
It can be assumed that some of the PCNPs who completed and 
returned the CJGC Survey work in settings that impose 
treatment protocols and may have influenced these PCNPs to 
respond habitually by protocol rather than treating each 
case scenario independently with consideration of all 
treatment options available to an PCNP.
The influence of pharmaceutical sales representatives 
and preceptor physicians also play a part in the way a 
PCNP treats hypertensive patients daily. Pharmaceutical 
sales representatives are constantly providing convincing 
data from studies they have conducted on the efficacy of 
their anti-hypertensive medicine and promote those 
medications under patent heavily. This generally means 
that they are out to influence PCNPs to prescribe newer 
agents without longstanding clinical trials rather than 
the promotion of older agents with many clinical trials 
that back their efficacy.
Physicians have preferences that affect PCNPs 
prescribing as they are respected for their medical 
knowledge and experience in the treatment of hypertension, 
especially if the PCNP is relatively inexperienced as a 
clinician and prescribes many of the same medicines as 
their preceptor to prevent confusion and conflict with the 
patients they treat together. Siegel and Lopez argued that
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many physicians are prescribing newer agents, such as 
calcium channel blockers and ACE inhibitors, as first-line 
agents in hypertension treatment rather than the use of 
beta-blockers and diuretics which have more long-term 
clinical trial support for their effectiveness (1997).
This pattern of prescriptive practice was seen by the 
PCNPs who answered the CJGC Survey as well, with ACE 
inhibitors and calcium channel blockers being prescribed 
more frequently than beta-blockers and diuretics for a 
stage one essential hypertensive patient (Case #1) when 
the decision to treat the patient pharmaceutically was 
chosen. The importance of this finding by the research 
data cannot be overlooked as it suggests that PCNPs are 
looking to referred knowledge instead of clinical research 
as a guide for practice which in the end threatens the 
professional ability of the PCNP to be an independent 
practitioner in the treatment of illness and places them 
in the role of a physician extender, which is not the role 
of the PCNP.
Lastly, patient compliance affects how PCNPs treat 
hypertensive patients. Every clinician knows that there is 
never a perfect treatment regimen, and patient preferences 
and health beliefs affect outcomes of therapy. Many times 
clinicians change their prescription practice and 
treatment regimens due to multiple failures with a
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treatment recommendation to produce a desired health 
change with their patients. This may have been the case in 
this study as many PCNPs did not treat an essential stage 
1 hypertensive patient (Case #1) with lifestyle 
modifications for a period of 6 months, which was a 
recommendation of the JNC VI guidelines for such patients. 
However, an PCNP feels about the success of lifestyle 
modification factors to lower blood pressure levels, it 
should be instituted because unneeded anti-hypertensive 
therapy has side effects and cost that could be avoided. 
Patients who are started on hypertensive medicines 
generally also remain on them for life.
It was ironic that many PCNPs in the study initiated 
treatment of a Stage 1 hypertensive patient with newer, 
more expensive agents rather than a cheaper diuretic such 
as hydrochlorothiazide, but many PCNPs would not order and 
echocardiogram or ECG in the diagnostic labs section of 
the case studies for the assumed purpose of not placing 
excessive cost on the patient. One echocardiogram or EKG 
to warrant the need for a newer more expensive agent is 
cheaper in the long-run than placing a patient with 
Medicare or Medicaid on an unneeded, expensive, newer, 
anti-hypertensive agent. Proper assessment of patients' 
cardiovascular status is important as well due to the fact 
that some patients with an MI would benefit from a beta-
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blocker as a person with congestive heart failure would 
benefit from an ACE inhibitor and a diuretic agent or 
combination. Based upon the findings in this study, PCNPs 
still need improvement in the area of cost consideration 
when contemplating the most efficient treatment for a 
patient.
The current study found that, although more PCNPs 
were partially or compliant with the JNC VI guidelines 
used in the CJGC Survey, many were noncompliant, and the 
largest number of PCNPs having only partial compliance.
NPs can use the results of this study to remind them of 
the importance of following competent, sound prescriptive 
practice daily to support their ability to treat illness 
as a primary care provider.
Upon analysis of the data and significant findings, 
the researcher was cognizant of King's Theory of Goal 
Attainment as a means of interpreting the data. The 
researcher found that the theory was appropriate to 
analyze the results as it dealt with patient treatment by 
PCNPs to meet a goal of appropriate blood pressure 
measurements through education and pertinent treatment 
strategies.
According to King's Theory of Goal Attainment, a 
nurse is a person with special health care knowledge and 
skills that can communicate this knowledge to patients
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through interactions to mutually set goals to achieve a 
state of health (King, 1995). The nurse uses specialized 
knowledge of treatment regimens to help patients chose 
interventions that will lead to the patient's desired 
health goals. The patient shares his health beliefs and 
feelings about various treatment options after weighing 
the benefits of each intervention and perceived outcome. 
This exchange of information, as described by King as a 
transaction, is essential to reach mutual goals which 
produce satisfaction when obtained (King, 1995). PCNPs are 
nurses with specialized knowledge to counsel and treat 
patients with health disturbances such as hypertension. 
PCNPs must be informed of the most recent scientific 
knowledge that supports the use if various different anti­
hypertensive regimens and their benefit to the patient, as 
well as competent in the prescribing of treatment regimens 
that will provide the most benefit to the patient.
Health care providers practice in the information 
generation where patients are researching the 
effectiveness of their providers' treatment 
recommendations with the recommendations of experts in 
diverse specialties of medicine and will more than likely 
increase in the future. PCNPs who do not stay up-to-date 
with the recommendations of expert committees, such as the 
JNC VI, take the risk of losing trust and the professional
87
respect of their patients and colleagues. Although the JNC 
VI guidelines are only recommendations, they are regarded 
by most health care professionals as the golden standard 
for hypertension management and should be employed and 
utilized as much as possible. There will always be cases 
of extenuating circumstance, but this does not mean that 
we should "throw the baby out with the bath water." The 
JNC VI guidelines are sound principles for hypertension 
treatment and provide legal protection to NPs if utilized 
in their treatment regimens. If PCNPs fail to share the 
knowledge of these guidelines with patients, specialized 
knowledge concerning a health condition is not shared, 
transactions are threatened, and goals may be unobtained.
Limitations
There were potential limitations to the 
generalization of the results. The cost incurred by the 
mailing and reproduction of the CJGC Survey and post card 
questions limited the researcher to send out only 200 CJGC 
Surveys and postcards which only yielded 37 PCNPs for the 
study. Due to the high cost of copies and postage, the JNC 
VI awareness question on the postcard was sent with the 
second mailing of the CJGC Survey and could have created 
insight, therefore biases, into the purpose of the study. 
However, the surveys that were returned with the postcards
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did not have higher scores than those surveys returned 
without the JNC VI awareness question included.
Another limitation to the study was the lack of 
biographical data that could have assessed for extraneous 
variables that could alter the results of the study. The 
biographical data sheet did not assess for bias that may 
have been caused by PCNPs working under strict 
hypertension management protocols, which was mentioned 
earlier as a possible cause for noncompliant responses. 
Also, it would have been helpful to have a self-report on 
how highly PCNPs believed their prescriptive practice 
habits were affected by preceptor preference or 
pharmaceutical sales information to rule this out as a 
possible cause for noncompliance.
Significance to Nursing
Many NPs are currently fighting for the ability to 
prescribe controlled substances to their patients. The 
analysis of the data concerning prescriptive practice that 
was in compliance with the JNC VI guidelines found that 
more PCNPs (n = 23) were partially compliant or compliant 
in the CJGC Survey than those PCNPs (n = 13) who were not 
compliant. The majority of these PCNPs were only partially 
compliant, and there were only three guidelines used for 
scoring of this compliance. Anti-hypertensive medications
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can have serious consequences if not prescribed 
competently. Hypotension, rebound tachycardia, heart block 
progression, bradycardia, and dizziness are all possible 
side effects or adverse effects of anti-hypertensive 
medications if prescribed carelessly. Controlled 
substances also can have serious side effects and adverse 
effects when prescribed incompetently, such as respiratory 
compromise, overdose, addiction, and an increased 
susceptibility to accidents and falls. The examination of 
NPs' prescription of drugs with possible adverse 
consequences, such as anti-hypertensives, will be examined 
in the future to assess the NP's ability to prescribe 
drugs with possible adverse sequela competently and 
provide competent monitoring of their patients on such 
medications.
The results of this study should remind NP of the 
importance of adequately prescribing all medications by 
respected guidelines of various medical organizations to 
prevent a lack of trust by patients in the treatment of 
illness and to avoid legal and legislative pitfalls 
related to prescriptive practice.
Conclusions
The results of this study implicate that PCNPs are 
not functioning at a level of compliance in hypertension
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treatment consistent with the JNC VI guidelines. This 
evidenced noncompliance by PCNPs gives support to the need 
for further, different dissemination techniques of the JNC 
guidelines for hypertension management in the future.
These findings are supported by the study of Goldberg and 
colleagues, who found that intensive academic detailing 
programs and continuous quality improvement teams were 
unsuccessful in producing an overall higher degree of 
compliance to the JNC guidelines in health care providers 
in clinical settings (1998). The researcher found that 
King's Theory of Goal Attainment was appropriate to 
interpret the findings theoretically as it dealt with the 
role of the nurse/PCNP as a person with specialized 
knowledge in health care that must be shared and utilized 
effectively during patient interactions for goals to be 
set and obtained.
Recommendations
After extensive review of recent and past literature 
related to the compliance of health care providers with 
JNC hypertension management guidelines and the results of 
this study, the researcher makes the following 
recommendations to improve the knowledge of hypertension 
management related to JNC guidelines compliance in the 
future :
91
1. Dissemination of future guidelines should 
incorporate case studies into the education process along 
with current scientific research to justify the importance 
of evidenced-based medicine in practice. This approach 
would be most beneficial in the education programs of 
health care professionals, such as medical schools and NP 
programs, so that students have no preconceived or 
influenced opinion on hypertension treatment, but may be 
successful in the form of continuing education seminars. 
This approach also protects providers from feeling 
threatened by outside influences and would allow open 
discussion to help the health care provider gain valuable 
information on the reliability of the JNC guidelines in 
practice.
2. Replication of the study with a larger sample over 
a larger geographical area. This will help support or 
refute the results of this study and provide an analysis 
of data from which better generalizations can be made.
3. Conduction of research in the future of PCNPs' 
prescriptive practice and treatment regimens of other 
health care problems. Further outcomes-based research will 
point out areas of needed improvement in education and 
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Cagle's JNC VI Guidelines 
Compliance Survey
The following case studies were designed to assess the 
primary care nurse practitioners' management strategies 
related to hypertension. The information you provide is 
very important for recommendations in treatment of this 
"silent killer" and appreciated very much. Following the 
case studies, three categories of interventions will need 
to be completed: pharmacologic interventions, non­
pharma co logic interventions, and diagnostic tests. The 
pharmacologic and non-pharmacologic interventions will 
need to be handwritten (please be as detailed as 
possible). The diagnostic test portion can be checked for 
each test that you would order in each situation.
Thank you for your time and participation in this study. 
Please fill in personal information before starting as it 
is crucial to how your responses will be analyzed in the 
study.
Personal Data
What is your practice site?
O  a. Hospital clinic 
O  b . Free clinic 
O  c . Health Department 
ÜJ d. Private practice
Years of experience as a nurse practitioner:_______________
Your nurse practitioner specialty:
C3 a. Family nurse practitioner 
O  b . Adult nurse practitioner
Type of educational program attended:
O  a. Certificate 
O  b . Master's
Average number of patients with hypertension you see a 
day:__________________
CASE STUDIES START ON NEXT PAGE.
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Case #1
Mr. R., a 36 yr. old Caucasian male, who is slightly 
overweight, presented to the clinic 2 weeks ago for an 
insurance physical. He had an elevated B/P of 160/78, Body Mass 
Index (BMI) of 28,(BMI 25-29 is Overweight) and no other 
abnormal findings. He had no previous history of hypertension. 
His B/P was checked again one week later and was 156/80. Mr. R. 
came in today with a B/P reading of 154/88. He was hospitalized 
for a DVT at the age of 32 yrs. Mr. R. works as a contractor 
for a local real estate firm and states he is "under stress 
lately" due to the number of projects he is undertaking. Mr. R 
confirms use of oral tobacco products, one can a week, and poor 
diet due to being "on the run." Father has HTN. Grandfather on 
mother's side died at the age of 58 yrs of MI. KNDA. No Hx of 





Fasting glucose:_____________  Lipid Profile:___________  TSH
Echocardiography:____________
24-hour urinary protein/creatinine clearance:__________________
Electrolytes:____________________  EKG:_________________________
Other. Please specify and give rationale:
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Case #2 :
A 52 yr. old Hispanic female with a Hx of COPD and GERD 
presented to your clinic yesterday for her annual GYN exam, B/P 
was 178/80, HR 80. Pt. was informed to return to clinic 
tomorrow to recheck B/P. On return visit pt. C/0 of H/A with 
B/P OF 198/74, HR 78. Pt. took B/P last night at home while 
resting 168/78. Pt. is on Medicaid. Her granddaughter lives 
with her, and she helps raise three small grandchildren. NKDA, 
immunizations are up-to-date. No surgeries. She was Dx with 
atypical chest pain 3 yrs. ago. A stress test was done then 
and was "normal." She also had an ECHO and EKG and pt said 
that MD said that "left side of my heart is slightly enlarged." 
She was Dx with GERD 3 yrs ago and takes Prilosec 20 mg QD. She 
has had no chest pain since then. B/P has been treated for the 
past 6 yrs by taking HCTZ 25 mg QD. She denies SOB at rest but 
has periods of SOB with exertion and no chest pain since she 
started Prilosec 3 years ago. She has no history of vision 
problems or changes in vision. No tobacco or alcohol use. How 





Fasting glucose:_____________  Lipid Profile:___________  TSH:
Echocardiography:____________
24-hour urinary protein/creatinine clearance:___________________
Electrolytes:____________________  EKG:_________________________
Other. Please specify and give rationale:
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Case #3 :
Mr. G. a 45 yr. old African American male with a Hx of Type 1 
DM and HTN, presents to the clinic on a Monday with c/o 
weakness, and polyuria. He states his B/P medication is 
"messing up his love life." B/P is 174/92 mmHg. He smokes one 
pack of cigarettes daily, and drinks a 6 pack of beer on Friday 
and Saturday weekly. His father died of a stroke at the age of 
60 yrs. His mother is alive but has a Hx of chronic renal 
failure, HTN, and Type 1 DM. He is currently taking Prinivil 10 
mg BID but stopped 3 days ago due to the side-effects. The 
patient has worked in construction for 20 years and has medical 
insurance and a medicine card to cover prescriptions. Mr. G. 
is on NPH insulin 40 units in a.m. and 20 units PM. Pt states 





Fasting glucose:_____________  Lipid Profile:___________  TSH
Echocardiography:____________
24-hour urinary protein/creatinine clearance:__________________
Electrolytes:____________________  EKG:_________________________
Other. Please specify and give rationale:
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I am writing this letter to gather participants for my 
graduate research project on hypertension at the 
Mississippi University for Women. The study is focused on 
assessing family nurse practitioners' hypertension 
management strategies to ascertain how this "silent 
killer" is approached from both a nursing/caring modality 
and the medical/curing modality in practice. The results 
will be examined using King's Goal Attainment Theory and 
will be disseminated back to participants, at their 
discretion, following the completion of the study. An 
attached questionnaire using vignettes is included with 
instructions. This questionnaire will assess the family 
nurse practitioner in hypertension management practice in 
three areas: pharmacological, non-pharmacological, and 
diagnostic tests ordered. All information gathered from 
the study will be kept confidential and used only for the 
purpose of this study.
If you consent to participate, please fill out the 
questionnaire and return it in the pre-addressed, stamped 
envelope which has been provided. Please do not include 
your name or address on the envelope to ensure 
confidentiality. Your informed consent to participate in 
the study will be implied with the return of the 
questionnaire. You will be able to withdraw from the study 
at any time, although any data already provided cannot be 
removed from the study due to its anonymous nature.
Thank you for your time and consideration. If you have any 
questions concerning the study, please contact me by 
telephone, mail, or E-mail.
Sincerely,
Gregory N. Cagle, RN 
MUW FNP Student
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If you have already sent back the vignettes I sent as part of 
my research study, thank you for your participation. This 
research, as I explained in my previous letter, is part of my 
graduate program requirements at the Mississippi University for 
Women. Data you provided are greatly appreciated. Data should 
be analyzed soon along with the results. If you would like a 
copy of the results. E-mail me at the address above, and I will 
gladly send you the results of the study. For those who have 
not been able to send the vignettes back, I am writing you to 
remind you of the research study on hypertension that I am 
conducting as part of my graduate program at Mississippi 
University for Women. I am writing again to each prospective 
participant to ask for their participation in this study. If 
you think you can help, please send the questionnaire back by 
the end of the month. I have enclosed another questionnaire and 
a self-addressed, stamped envelope. Here is a brief description 
of the study again to help with your decision.
The study is focused on assessing primary care nurse 
practitioners' hypertension management strategies to ascertain 
how this "silent killer" is approached from both a 
nursing/caring modality and the medical/curing modality in 
practice. The results will be examined using King's Goal 
Attainment Theory and will be disseminated to participants, at
their discretion, following the completion of the study.
All information gathered from the study will be kept 
confidential and used only for the purpose of this study.
Please do not include your name or address on the envelope to
ensure confidentiality. Your consent to participate in the 
study will be implied with the return of the questionnaire. You 
will be able to withdraw from the study at any time, although 
any data already provided cannot be removed from the study due 
to its anonymous nature. I have one more request as part of the 
study. I am asking one qualitative question in the study to 
help explain the results obtained from the vignettes provided 
to each PCNP included in the study. The question is a postcard 
included with this letter and can be returned with the 
questionnaire or by itself in the self-addressed, stamped 
envelope provided. Your help with this part of the study will 
also be greatly appreciated as it is an essential part of the 
study for its completion. Once again, thank you for your time
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and help in this study. I thank you for your time and 
consideration. If you have any questions concerning the study, 
please contact me by phone, mail, or E-mail.
Sincerely,
Gregory N. Cagle, RN 
MUW FNP Student
APPENDIX E 
JNC VI AWARENESS QUESTION/POSTCARD
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Please answer and return the following research 
question:
Are you aware of the current national guidelines 
(The Sixth Report of The Joint National 
Committee on the Prediction, Detection, 
Evaluation, and Treatment of High Blood 
Pressure) for hypertension management?
Yes : 0 
No: 0
(Fill in oval with black ink pen, please)
